Director, Cancer Biology Division
(313) 577-1018
k.v.honn@wayne.edu
431 Chemistry Bldg., Detroit, Michigan 48202

Fax

(313) 577-0798

Education

B.S., Wayne State University, 1967
    Major:  Biological Sciences
    Minor:  Chemistry

M.S., Wayne State University, 1968
    Major:  Biological Sciences
    Minor:  Chemistry

Ph.D., Wayne State University, 1977
    Major:  Endocrinology
    Minor:  Biochemistry
    Cognate:  Radiobiology

Research Interest

Eicosanoids and integrins in metastasis; prostate cancer; angiogenesis and hypoxia; lipoxygenases and tumor cell apoptosis and cell cycle regulation; lipoxygenase targets for novel therapies

Curriculum Vitae

Institutional Address:                  Department of Radiation Oncology

                                                   431 Chemistry Building

                                                   Wayne State University

Education:                Wayne State University              B.S., 1967

Wayne State University              M.S., 1968

Wayne State University              Ph.D., 1977

2004 – Present           Distinguished Professor of Radiation Oncology and Pathology                  

1993—2004                Professor, Wayne State University, School of Medicine, Department of Pathology

1984—2004                Professor, Wayne State Univ., School of Medicine, Dept. of Radiation Oncology

1988—Present            Adjunct Professor, Wayne State University, Department of Chemistry

1984—1988                Adjunct Professor, Wayne State University, Department of Biological Sciences

1981—1984                Associate Professor, Wayne State University, School of Medicine, Department of Radiation Oncology

1981—1984                Associate Professor, Wayne State Univ., School of Medicine, Dept. of Radiology

1981—1984                Adjunct Associate Professor, Wayne State Univ., Dept. of Biological Sciences

1979—1981                Assistant Professor, Wayne State University, School of Medicine, Department of Radiation Oncology

1978—1981                Adjunct Assistant Professor, Wayne State Univ., Dept. of Biological Sciences

1977—1981                Assistant Professor, Wayne State Univ., School of Medicine, Dept. of Radiology

Hospital and Professional Appointments

1995 – Present           Member, Karmanos Cancer Institute

1982—Present            Head, Cancer Biology Div., Gershenson Radiation Oncology Center, Harper Hospital.

1984—1995                Adjunct Scientist, Michigan Cancer Foundation.

1982—1990                Scientific Associate, Medical Staff, Harper Hospital.

1980—1990                Scientific Associate, Medical Staff, Detroit Receiving Hospital.

1978— 1979               Director, Physicians Radioimmunoassay Laboratory, Southfield, Michigan.

1977—1980                Scientific Associate, Medical Staff, Detroit General Hospital.

1974—1977                Research Assistant, Wayne State Univ., School of Medicine, Dept. of Radiology.

Instructional Service

·         Anatomy and Physiology

·         Methods in Endocrinology

·         Methods in Radiobiology

·         Vertebrate Physiology

·         Radiobiology for Diagnostic Radiology Residents

·         Radiobiology for Radiation Oncology Residents

·         Advances in Cancer Biology

·         Cancer Biology

·         Introduction to Biomedical Research

B.      Contribution to undergraduate research training:

Developed a course, Introduction to Biomedical Research, at undergraduate and honors level. Mentored and trained over 224 undergraduate students in independent research projects and published 90 papers with undergraduates as coauthors.

C.      Contribution to graduate and postgraduate research training:

Trained ten graduate students with three currently under training. Trained twenty-two postdoctoral fellows with an additional two in training,. Served on over 30 graduate research student progress committees, published 165 papers with graduate students and postdoctoral fellows as coauthors or first authors. 

D.      Contribution to ongoing training:

         Hosted six scientists for a minimum of one year as visiting scientists on sabbatical leave.

         "The role of prostaglandins in ACTH induced steroidogenesis: Direct effects of prostaglandins on isolated bovine adrenocortical mitochondria."

         “Tumor cytoskeleton and tumor cell induced platelet aggregation.”

3.      Alex Zacharek, M.S., 2003

“G-protein-coupled receptors: structure, function, and role in drug discovery.”

4.                 Kevin Wickenheiser, M.S.,2007

“Function of Soluble Selectins”

         "Purification and characterization of tumor derived platelet aggregating and procoagulant activity."

         "Tumor cell interactions with platelets, endothelial cells and extracellular matrix."

         "The regulation of arachidonic acid metabolsim in the murine Lewis lung carcinoma and the B16 amelanotic melanoma"

         "Role of the Tumor Cell Cytoskeleton in Metastasis"

         "Eicosanoid Metabolite Regulation of Tumor Cell Integrin aIIbb3 During Tumor Cell Adhesion in Metastasis"

         "12(S)-HETE and 13(S)-HODE Regulation of Protein Kinase C: Role in Tumor Cell Metastasis"

         "Molecular Studies on Tumor Cell-Vasculature Interactions:  Adhesion Molecules, Endothelial Cell Retraction, Tumor Cell Spreading, and the Modulatory Role of Eicosanoid 12(S)-HETE"

         “Mechanisms of Inactiation of Multiple Tumor Suppressor Genes in Human Prostate Cancer”.

9.      Charlie Szekeres, 2000

10.         Keqin Tang, 2000

“Regulation of arachidonate 12-liponxyenase and its role in tumor cell apoptosis”.

              “12-Lipoxygenase And Prostate Cancer Angiogenesis In The Normoxic And Hypoxic Microenvironment”

·         Paul Tressel 1982—1984

·         Andrew Bajkowski 1982—1985

·         James Onoda 1982—1985

·         Tamara Lah 1985—1987

·         Bruce Steinert 1985—1988

·         Kamiar Moin 1986—1988

·         Marek Malecki 1988—1989

·         Young Sook Chang 1987—1990

·         Marek Wojtukiewicz 1989—1990

·         Yong Quan Chen 1990—1993

·         John Davies 1992—1993

·         Zofia Duniec 1990—1994

·         Edgar Ben Joseph 1993—1994

·         Bin Liu 1994

·         Dean G. Tang 1994—1996

·         Gholamreza Sheikhnejad 1994—1996

·         Rudolph Mihalik - 1995—1996

·         Mohit Trikha 1994—1997

·         Daotai Nie 1997 - 2001

·         Mustapha Kandouz 1999- 2001

·         Keqin Tang 2000-2002

·         Graham Pidgeon 2001-2002

·         Jin Rongxian 2002-Present

·         Yande Guo 2002-Present

H.      Current Graduate Students:

c. Kevin Wickenheiser – BMS Program

1.      Marek Wojtukiewicz 1992—1993

         Senior Assistant

         Department of Hematology

2.      Wolfgang Hagmann 1992—1994

         Associate Professor

         Department of Tumor Biochemistry

         German Cancer Research Center

         Heidelberg, Germany

3.      Igor Butovich , Ph D.1994 - 1995

         Head, Laboratory of Chemical Enzymology

         Institute of Bio-Organic Chemistry

         Murmanskaya Str. 1

         Kiev, 253660, Ukraine

4.      Jozsef Timar 1990-1993, 1996-2000

Professor and Chair

Department of Tumour Progression

National Institute of Oncology

Budapest, Hungary.

5.      Jozsef Lovey, 2002

         Assistant Professor

         Department of Tumour Progression

         National Institute of Oncology

         Budapest, Hungary

6.      Erzsebet Raso, 2002

         Assistant Professor

         Department of Tumour Progression

         National Institute of Oncology

         Budapest, Hungary

7.       Vladimir Yu. Serebrov, MD, PhD, DMSci, 2006

Chairman of Biochemistry and Molecular Biology Dept

Director of International Affair Dept

ADMINISTRATIVE ACTIVITIES

·         President's Commission on Long Range Capital Programs, 1974—1975.

·         Radiation Safety and Radioisotope Committee, Wayne State University, 1978—2003.

·         Chairman, Audit Subcommittee of the Radiation Safety & Radioisotope Committee, 1980—2002.

·         Research Equipment Review Committee, Wayne State University, 1986—1987.

·         Internal Advisory Comm. for the Inst. of Chemical Toxicology, Wayne State Univ., 1986—1987.

·         Review Committee, American Cancer Society, Wayne Chapter, 1986—2000.

·         Member, Chairman Search Committee I, Radiation Oncology Department, Wayne State

·         University, School of Medicine, 1988—1989.

·         Member, Chairman Search Committee II, Radiation Oncology Department, Wayne State

·         University, School of Medicine, 1990—1991.

·         Distinguished Faculty Fellowship Committee, Wayne State University, 1997.

·         Chairman, Scientific Misconduct Committee, (AdHoc) Wayne State University, 1997.

·         Member, Library committee, Wayne State University, 2002-present.

·         Five Year Review Committee for Department of Radiation Oncology

·         Director, Prostate Research Initiative, Wayne State University, 1995--2001.

·         Senior Leadership, Member, Dept. of Radiation Oncology, Wayne State Univ. 1999 —2002.

·         Research & Education Committee, Chair, Dept. of Radiation Oncology, Wayne State Univ. 1999 —2002.

·         Research Committee, Dept. of Radiation Oncology, Wayne State University, 1984—1999.

·         Promotion & Tenure Committee, Dept. of Radiation Oncology, Wayne State Univ., 1984—2002.

·         Graduate Committee, Dept. of Radiation Oncology, Wayne State University, 1987—Present.

·         Planning & Priorities Committee, Dept. of Radiation Oncology, Wayne State Univ, 1991—2002.

·         Executive Committee, Department of Radiation Oncology, Wayne State Univ., 1992—1999.

·         Space Committee, Department of Pathology, Wayne State University, 1992—1993 (Chairman).

·         Research Committee, Department of Pathology, Wayne State University, 1995-Present

D. Karmanos Cancer Institute Committees

·         Director, Urologic Oncology Program, 1999 - 2003

·         Associate Director, Urologic Oncology Program, 1995--1999

·         Director, Prostate Initiative, 1995-2001

·         Chairman, Prostate Initiative Steering Committee

·         Program Leader, Prostate Program

·         Member, KCI Program Leadership Committee

·         Prostate Initiative Internal Scientific Review Committee

·         Karmanos Cancer Institute Patent Committee

·         Prostate Cancer Advisory Committee

·         Radiation Safety and Radioisotope Committee, Detroit Receiving Hospital, 1993—1997.

·         Advisory Committee for the Clinical Oncology Research Career Dev. Program, 1991—1995.

·         Secretary, Radiation Oncology Research and Development Center, 1997-2004.

·         Finance Committee, Radiation Oncology Research and Development Center, 1986—2002.

·         Research Committee, Radiation Oncology Research and Development Center, 1991—2002

·         Chairman, Research Subcommittee, Michigan Prostate Cancer Advisory Committee, 1996-2003

·         Member, Michigan Dept. of Community Health, Prostate Cancer Advisory Committee, 1996 — 2003

·         Member, Board of Directors, Academic Radiation Oncologists, 2003-2005

·         Secretary, Cancer Research Foundation, 2004 – Present

·         President, Eicosanoid Research Foundation, 2004 – Present

·         Board of Directors, Biomide Corporation, 1992 – Present

·         Board of Directors, iXL Group, 2003 – Present

·         Board of Directors, Metastasis Research Society, 2000 – Present

·         Coeditor-in-Chief, Cancer and Metastasis Reviews, 2001-Present

·         Member, Editorial Board Prostaglandins , 1984—1997.

·         Member, Editorial Board Prostaglandins and Other Lipid Mediators, 1997 - Present

·         Member, Editorial Board Invasion and Metastasis, 1986—2000.

·         Member, Editorial Board Eicosanoids, 1991—1992.

·         Member, Editorial Board Inter. J. Immunopathology and Pharmacology, 1991—Present

·         Member, Editorial Board Cancer Metastasis Reviews, 1992—2001.

·         Member, Editorial Board Cancer Molecular Biology Journal, 1993—Present

·         Member, Editorial Board Pathology and Oncology Research, 1994—Present

·         Member, Editorial Board International Journal of Oncology, 1997 - Present

·         Member, Editorial Board Current Opinion in Oncologic, Endocrine & Metabolic Investigational    Drugs, 1999 - Present

·         Member, Editorial Board Nutrition and Cancer, 2004-Present

·         Member, Editorial Board European Journal of Inflammation, 2006-Present

International Journal of Radiation Biology

Proceedings of the National Academy of Sciences

Prostaglandins, Leukotrienes, and Essential Fatty Acids

·         Organizing Committee, International Conf. on Prostaglandins and Cancer, Washington DC, 1981.

·         Reviewer (ad hoc), National Science Foundation, 1982—1997.

·         Reviewer (ad hoc) Veterans Administration, 1982—Present.

·         Reviewer (ad hoc) Heart Lung and Blood Institute NIH, 1982—1988.

·         Reviewer (ad hoc) Experimental Therapeutics I Study Section National Cancer Inst., NIH, 1987.

·         Organizing Committee, International Conference on Mechanisms of Metastasis: Potential Therapeutic Implications, Detroit, Michigan, 1984.

·         Organizing Committee, Lake Ontario Metastasis Group Meeting, Detroit, Michigan, 1988.

·         Organizing Committee, First International Conference on Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury, Detroit, Michigan, 1989.

·         Organizing Committee and Co-chairperson, Eicosanoids in Cancer Cell Metastasis, 7th International Conference on Prostaglandins and Related Compounds, Florence, Italy, 1990.

·         Organizing Committee, Second International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Berlin, 1991.

·         Board of Directors, Metastasis Research Society, 1990—1992.

·         Chairman, Organizing Committee, Third International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Washington D.C., 1993.

·         Chairman and Organizer, Eicosanoids and Cell Proliferation Symposium, Winter Prostaglandin Meeting, Keystone, CO, 1993.

·         Organizing Committee, Fourth International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Hong Kong, 1995.

·         Organizing Committee, Fifth International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, La Jolla, CA, 1997.

·         Organizing Committee, Sixth International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Boston, MA, 1999.

·         Board of Directors, Metastasis Research Society, 1998 -- 2000.

·         Organizing Committee Seventh International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Nashville, TN, 2001.

·         Chairman, Organizing Committee Eighth International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Chicago IL, 2003.

·         Chairman, Organizing Committee Ninth International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, San Francisco, 2005.

·         Chairman, Executive Committee Tenth International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, Montreal Canada, 2007.

·         Reviewer (ad hoc), Veterans Administration

·         Reviewer (ad hoc), Vanderbilt University-Ingram Cancer Center

·         Member NCI Scientific Review Group Subcommittee C (Basic and Preclinical Sciences Program Project grants)

·         Member Special Emphasis Panel/ZGM1 PPBC 6 (CP): National Institute of General Medical Sciences/NIH

·         Member NCI Scientific Review Group Subcommittee E (Prevention Program Project Grants)

·         NCI Program Project Cluster Review, January 2006

·         NIEHS – Director’s Challenge, Review Panel, August 15-16, 2006

·         NCI - Discovery & Development Special Emphasis Panel, June 6-7, 2007

·         DOD – 2007 Prostate Cancer Research Program. Peer Review Panel Member, July 8-10, 2007

·         NCI Discovery & Development Grant Reviews, February 5-8, 2008

PROFESSIONAL AFFILIATIONS

·         American Association for the Advancement of Science

·         American Association for Cancer Research

·         American Chemical Society

·         American Physiological Society

·         American Society for Cell Biology

·         American Society of Zoologists

·         Comprehensive Cancer Center of Metropolitan Detroit

·         Endocrine Society

·         Federation of American Societies for Experimental Biology

·         International Society for Thrombosis and Hemostasis

·         New York Academy of Sciences

·         Radiation Research Society

·         Sigma Xi

·         Society for Experimental Biology and Medicine

·         NSF Summer Trainee, 1972

·         Sigma Xi Research Award, 1974

·         Graduate Fellowship, Wayne State University, 1974—1975

·         Outstanding Paper in Ozone Research Award; International Ozone Association, 1979

·         Probus Club Award for Academic Achievement, 1982

·         Wayne State Fund Career Development Chair, 1983—1984

·         Board of Governors Faculty Recognition Award, 1983

·         Board of Governors Faculty Recognition Award, 1985

·         Board of Governors Distinguished Faculty Fellowship Award, 1996

·         Board of Governors Citation “most cited Wayne State University faculty member” - 1983-1993.

·         CaPCure Research Award, 1998.

·         Appointment to Distinguished Professor, 2004.

1.  Inhibition of tumor growth and metastasis with calcium channel blocker compounds. (U.S. Patent No. 4,690,935; Issue Date 9/1/1987).

2.   4-(Nitrone Aryl) dihydropyridines. (U.S. Patent No. 4,758,669; Issue Date 7/19/1988).

3.   Method for treating human tumor cell metastasis. (U.S. Patent No. 4,760,066; Issue Date 7/26/1988).

4.   Method and compositions for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class. (U.S. Patent No. 4,906,646; Issue Date 3/6/1990).

5.   Method and compositions for inhibition of tumor cell induced platelet aggregation. (U.S. Patent No. 4,950,680; Issue Date 8/21/1990.

6.   Cyclic hydroxamic acids. (U.S. Patent No. 5,234,933; Issue Date 8/10/1993).

8.   Cyclic hydroxamic acids. (U.S. Patent No. 5,292,884; Issue Date 3/8/1994).

9.   Methods for testing for the presence of metastatic tumor cells. (U.S. Patent No. 5,378,607; Issue Date   1/3/1995).

10. Methods for measuring blood procoagulant activity of human leukocyte antigens. (U.S. Patent No. 5,529,934; Issue Date 6/25/1996).

11. Method For Induction Of Tumor Cell Apoptosis With Chemical Inhibitors Targeted To 12-Lipoxygenase. (U.S. Patent No. 5,861,268;   Issue Date 1/19/1999).

12. Nucleic Acids Encoding Truncated Integrains. (U.S. Patent No. 6,046,316; Issue Date 4/4/2000).

13. Antibodies Specific for Soluble Truncated Integrins. (U.S. Patent No. 6,218,514; Issue Date 4/17/2001).

14. Inhibitors of 12-Lipoxygenase as Radiosensitizers for Radiation Treatment of Cancer. (U.S. Provisional Patent Application S.N. 60/691,452 filed June 16, 2005).

CONSULTING ACTIVITIES

·         Bayer AG  1981-1983.

·         Upjohn Company 1981.

·         Ciba-Geigy 1981-1983.

·         E.I. DuPont de Nemours and Company 1984.

·         Pfizer 1983.

·         Thomae Pharmaceuticals 1984-1989.

·         Squibb 1985.

·         Ono Pharmaceuticals 1988-1992.

·         BioMol 1992.

·         Wellcome Foundation, Inc. 1991-1993.

·         Schering A.G. 1986-1993.

·         Ferndale Laboratories 1993-1995

·         Biodale Laboratories 1994 -1995

·         Biomide Corporation 1992-Present

·         Chyron Corporation 2002-Present

·         Berlex Corporation 2000-Present

·         Oxford Biomedical Research

·         Centocor Corporation

CURRENT RESEARCH INTERESTS

·         Role of cyclooxygenase (i.e., prostaglandins) and lipoxygenase (i.e., leukotrienes, hydroxy fatty acids) metabolites of polyunsaturated fatty acids in tumor growth and metastasis.

A. Published Manuscripts

2. Honn, K.V. and W. Chavin. 1975. An improved automated biuret method for the determination of microgram protein concentrations. Anal. Biochem. 68:230-235.

3. Honn, K.V., J.A. Singley and W. Chavin. 1975. Fetal bovine serum: A multivariate standard. Proc. Soc. Exp. Biol. Med. 149:344-347.

4. Taylor, J.D., K.V. Honn and W. Chavin. 1975. Adrenocortical ultrastructure in the squaliform elasmobranch (Gingliomostoma cirratum Bonnaterre): Cell death, a postulate for holocrine secretion. Gen. Comp. Endrocrinol. 27:358-370.

5. Honn, K.V. and W. Chavin. 1975. Prototype design for a closed marine system employing quarternary water processing. Marine Biol. 31:293-298.

6. Honn, K.V. and W. Chavin. 1976. Utility of ozone treatment in the maintenance of water quality in the closed marine system. Marine Biol. 34:201-209 .

7. Honn, K.V., G.M. Glezman and W. Chavin. 1976. A high capacity ozone generator for use in acquaculture and water processing. Marine Biol. 34:210-216.

8. Honn, K.V. and W. Chavin. 1976. In vitro trophic action of ACTH and insulin upon adrenocortical enzymes of the squaliform Gingliomostoma cirratum (Bonnaterre). Gen Comp. Endocrinol. 29:360-368.

9. Kimura, T., H.P. Wang, L.R. de Alvare, K.V. Honn and W. Chavin. 1976. Cytochrome P-450 and adrenodoxin in adrenal mitochondrial fraction of several lower vertrebrates. Comp. Biochem. Physiol. 53B:273-276.

10. Honn, K.V. and W. Chavin. 1976. Role of prostaglandin modulation on the mechanisms of ACTH action in the human adrenal. Biochem Biophys. Res. Commun. 73:164-170.

11. Honn, K.V. and W. Chavin. 1976. Role of prostaglandins in aldosterone production by the human adrenal. Biochem. Biophys. Res. Commun. 72:1319-1326.

12. Honn, K.V. and W. Chavin. 1977. Antagonistic action of E and F series prostaglandins upon mineralocorticoid production by the human adrenal. Experientia 33:398-400.

13. Honn, K.V. and W. Chavin. 1977. Temporal effects of ACTH, indomethacin and 7-oxa-13-prostynoic acid upon glucocorticoid production by the human adrenal. Experientia 33:545-546.

14. de Alvare, L.R., T. Kimura, A. Singhakowinta, K.V. Honn and W. Chavin. 1977. Mitochondrial redox components of human adrenocortical steriod hydroxylases under physiological conditions and in focal hyperplasia of the zona fasiculata. ACTA Endocrinol. 84:780-788.

15. Neale, N., K.V. Honn and W. Chavin. 1977. Hematological Responses to thermal acclimation in a cold water squaliform.   (Heterodontus francisci Girard). J. Comp. Physiol. 115:215-222.

16. Abramowitz, J., K.V. Honn and W. Chavin. 1977. Effect of environmental temperature upon rates and duration of hemolysis of squaliform erythrocytes. Comp. Biochem. Physiol. 57A-229-230.

17. Honn, K.V. and W. Chavin. 1977. In vitro ACTH stimulation of corticosterone output in relation to cyclic nucleotide alterations in the crocodilian (Caiman sclerops) adrenal. Gen. Comp. Endocrinol. 32:330-340.

18. Honn, K.V. and W. Chavin. 1977. Effects of A and B series prostaglandins on cAMP, cortisol and aldosterone production by the human adrenal. Biochem. Biophys. Res. Commun. 76:977-982.

19. Honn, K.V. and W. Chavin. 1977. In vitro temporal cAMP and cortisol responses to ACTH by the normal human adrenal gland. ACTA Endocrinol. 85:823-831.

20. Honn, K.V. and W. Chavin. 1977. In vitro cAMP, cortisol and aldosterone responses of adult human adrenocortical tissue to ACTH and human growth hormone. Experientia. 33:1327-1328.

21. Honn, K.V., W. Chavin and A. Singhakowinta. 1977. In vitro responses of focal hyperplastic tissue of the human adrenal zona fasciculata to ACTH. ACTA Endocrinol. 86:363-368.

22. Honn, K.V. and W. Chavin. 1978. Temporal effect of prostaglandins E and F on human adrenal cAMP and cortisol output. Life Science. 22:543-552.

23. Honn, K.V. and W. Chavin. 1978. In vitro effects of theophylline and aminogluthetimide upon basal and ACTH stimulated cAMP levels and steriod output by the normal human adrenal gland. ACTA Endocrinol. 88:354-363.

24. Chavin, W., K.V. Honn, and P. J. Clifford. 1978. cAMP involvement in the control of corticosterone and aldosterone output in the adrenal of the frog (Rana berlandieri forreri). Gen. Comp. Endocrinol. 35:445-450.

25. Honn, K.V. and W. Chavin. 1978. In vitro tropic action of ACTH upon adrenocortical cyclic nucliotides (cAMP, CGMP) and corticosterone output in blue (Prionace gluaca Linnaeus) and in mako (Isurus oxryhincus Rafinesque) sharks. Gen. Comp. Endocrinol. 36:161-169.

26. Chavin, W., K.V. Honn and P.J. Clifford. 1978. Prostaglandin effects upon cAMP levels, corticosterone output and aldosterone output in the adrenal of the frog (Rana berlandieri forreri). Gen. Comp. Endocrinol. 36:442-450.

27. Honn, K.V. 1979. Ozonation as a critical component of closed marine system design. Ozone: Science Eng. 1:11-29.

28. Honn, K.V., J.R. Dunn II, L.R. Morgan, M. Bienkowski and L.J. Marnett. 1979. Inhibition of DNA systhesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: Comparison with chemotherapeutic agents. Biochem. Biophys. Res. Commun. 87:795-801.

29. Battista, J.R. and K.V. Honn. 1980. The effect of prostaglandins on 11-b-hydroxylase activity in bovine adrenocoritcal mitochondria. Biochem. Biophys. Res. Commun. 93:1104-1109.

30. Honn, K.V., B. Cicone, and A. Skoff. 1981. Prostacyclin: A potent antimetastatic agent. Science 212:1270-1272.

31. Honn, K.V., M. Romine, and A. Skoff. 1981. Prostaglandin analogs as inhibitors of tumor cell DNA synthesis. Proc. Soc. Exp. Biol. Med. 166:562-567.

32. Sloane, B.F., J.R. Dunn, and K.V. Honn. 1981. Lysosomal cathepsin B: Correlation with metastatic potential. Science 212: 1151-1153.

33. Honn, K.V. and J. Meyer. 1981. Thromboxanes and prostacyclin: Positive and negative modulators of tumor growth. Biochem. Biophys. Res. Commun. 102:1122-1129.

34. Sloane, B.F., K.V Honn, J.G. Sadler, W.A. Turner, J.J. Kimpson and J.D. Taylor. 1982. Cathepsin B activity in B16 melanoma cells: A possible marker for metastatic potential. Cancer Res. 42:980-986.

35. Honn, K.V. and J.R. Dunn II. 1982. Nafazatrom (Bay g 6575) inhibition of tumor cell, lipoxygenase activity and cellular proliferation. FEBS Lett. 139:65-68

36. Honn, K.V., P. Cavanaugh, C. Evens, J.D. Taylor, and B.F. Sloane. 1982. Tumor cell-platelet aggregation: Induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science. 217: 540-542.

37. Honn, K.V. 1983. Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin. Exp. Metastasis 1:103-114.

38. Honn, K.V., J.M. Onoda, C.A. Diglio and B.F. Sloane. 1983. Calcium channel blockers: Potential antimetastatic agents. Proc. Soc. Exp. Cell. Biol. Med. 174:16-19.

39. Cavanaugh, P.G., B.F. Sloane, A.S. Bajkowski, G.J. Gasic, T.B. Gasic and K.V. Honn. 1983. Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin. Exp. Metastasis 1:297-307.

40. Krug, E.C., K.V. Honn, J. Battista and C.S. Nicoll. 1983. Corticosteriods in serum of Rana catesbeiana during development and metamorphosis. Gen. Comp. Endocrinol. 52:232-241.

41. Menter, D., J.M. Onoda, J.D. Taylor and K.V. Honn. 1984. Effects of prostacyclin (PGI2) on tumor cell induced platelet aggregation. Cancer Res. 44:450-456.

42. Honn, K.V., J.M. Onoda, C.A. Diglio, M.M. Carufel, J.D. Taylor and B.F.Sloane. 1984. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker nimodipine. Clin. Exp. Metastasis. 2:61-72.

43. Onoda, J.M., B.F. Sloane, and K.V. Honn. 1984. Antithrombogenic effects of calcium channel blockers: Synergism with prostacyclin and thromboxane synthase inhibitors. Thromb. Res. 34:367-378.

44. Honn, K.V. , J.M. Onoda, D.G. Menter, J.D. Taylor, and B.F. Sloane. 1984. Arachidonic acid metabolism as a target for antimetastatic agents. Cancer Bull. 36:200-204.

45. Sloane, B.F., J.G. Sadler, C. Evens, R. Ryan, A.S. Bajkowski, J.D. Crissman and K.V. Honn. 1984. Cathepsin B-like cysteine proteinases and tumor metastasis. Cancer Bull 36:196-200.

46. Marnett, L.J., P.H. Siedlik, R. Ochs, M. Das, K.V. Honn, R. Warnock, B. Tainer and T.E. Eling. 1984. Stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, Nafazatrom. Mol. Pharmacol. 26:328-335.

47. Samokyszyn, V.M., B.F. Sloane, K.V. Honn and L.J. Marnett. 1984. Cooxidation of 13-cis-retinoic acid by prostaglandin H synthase. Biochem. Biophys. Res. Commun. 124:430-436.

48. Honn, K.V., J.M. Onoda, K. Pampalona, M. Battaglia, G. Neagos, J.D. Taylor, C.A. Diglio and B.F. Sloane. 1985. Inhibition by dihydropyridine class channel blockers of tumor cell-platelet-endothelial cell interactions in vitro and metastasis in vivo. Biochem. Pharmacol. 34:235-241.

49. Cavanaugh, P.G., B.F. Sloane, J.D. Taylor, A.S. Bajkowski and K.V. Honn. 1985. Purification and characterization of a platelet aggregating activity from tumor cell: co-purification with procoagulant activity. Thromb. Res. 37:309-326.

50. Honn, K.V. Honn and L.J. Marnett. 1985. Requirement of a reactive a, b-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by “A” series prostaglandins. Biochem. Biophys. Res. Commun. 129:34-40.

51. Ryan, R.E., J.D. Crissman, K.V. Honn and B.F. Sloane. 1985. Cathepsin B-like activity in viable tumor cells isolated from rodent tumors. Cancer Res. 35:3638-3641.

52. Crissman, J.D., J. Hatfield, M. Schaldenbrand, B.F. Sloane, and K.V. Honn. 1985. Arrest and extravasation of B16 amelanotic melanoma cells in murine lungs. Lab. Invest. 53:470-478.

53. Onoda, J.M., J.R. Jacobs, J.D. Taylor, B.F. Sloane and K.V. Honn. 1986. Cisplatin and nifedipine: Synergistic cytotoxicity against murine solid tumors and their metastasis. Cancer Lett. 30: 181-188.

54. Sloane, B.F., J. Rozhin, K. Johnson, H. Taylor, J.D. Crissman and K.V. Honn. 1986. Cathepsin B:  Association with plasma membrane in metastatic tumors. Proc. Nat. Acad. Sci. (USA) 83:2483-2487.

55. Menter, D.G., J.S. Hatfield, C. Harkins, B.F. Sloane, J.D. Taylor, J.D. Crissman and K.V. Honn. 1987. Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clin. Exp. Metastasis. 5:65-78.

56. Menter, D.G., J.M. Onoda, D. Moilanen, B.F. Sloane, J.D. Taylor and K.V. Honn. 1987. Inhibition by prostacyclin of the tumor cell induced platelet release reaction. J. Natl. Cancer Inst. 78:961-989.

57. Honn, K.V., B. W. Steinert, J.M. Onoda and B.F. Sloane. 1987. The role of platelets in metastasis. Biorheology. 24:127-137.

58. Menter, D.G., B.W. Steinert, B.F. Sloane, J.D. Taylor and K.V. Honn. 1987. A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. Cancer Res. 47:2425-2432.

59. Menter, D.G., C. Harkins, J. Onoda, W. Riordan, B.F. Sloane, J.D. Taylor and K.V. Honn. 1987. Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: An ultrastructural study. Invasion Metastasis 7:109-128.

60. Honn, K.V., B.W. Steinert,., K. Moin,. J.M. Onoda,. J.D. Taylor,.and B.F. Sloane, 1987. The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation. Biochem. Biochys. Res. Commun. 145:384-389.

61. Menter, D.G., B.F. Sloane, B.W. Steinert, J. Onoda, R. Craig, C. Harkins, J.D. Taylor and K.V. Honn.  1987. Platelet enhancement of tumor cell adhesion to subendothelial matrix: Role of platelet cytoskeleton and platelet membrane. J. Natl. Cancer Inst. 79:1077-1090.

62. Rozhin, J., D. Robinson, M.A. Stevens, T.T. Lah, K.V. Honn, R.E. Ryan and B.F. Sloane. 1987. Properties of plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic melanoma variants. Cancer Res. 47:6620-6628.

63. Menter, D.G., B. W. Steinert, B.F. Sloane, N. Gundlach, C.Y. O’Gara, L.J. Marnett, C. Diglio, D. Walz, J.D. Taylor and K.V. Honn. 1987. Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Res. 47:6751-6762.

64. Grossi, I.M., L.H. Fitzgerald, A. Kendall, J.D. Taylor, B.F. Sloane and K.V. Honn. 1987. Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proc. Soc. Exp. Biol. Med. 186:378-383.

65. Onoda, J.M., K.K. Nelson, I.M. Grossi, L.A. Umbarger, J.D. Taylor and K.V. Honn. 1988. Separation of high and low metastatic subpopulations from solid tumors by centrifugal elutriation. Proc. Soc. Exp. Biol. Med. 187:250-255.

66. Onoda, J.M., K.K. Nelson, J.D. Taylor and K.V. Honn. 1988. Cisplatin and Nifedipine: Synergistic antitumor effects against an inherently cisplatin-resistant tumor. Cancer Lett. 40:39-47.

67. Grossi, I.M., J.S. Hatfield, L.A. Fitzgerald, M. Newcombe, J.D. Taylor and K.V. Honn. 1988. Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell-matrix interactions. FASEB J. 2:2385-2395.

68. Cavanaugh, P.G., B.F. Sloane and K.V. Honn. 1988. The role of the coagluation system in tumor cell induced platelet aggregation and metastasis. Haemostasis 18:37-46.

69. Chopra, H., J.S. Hatfield, Y.S. Chang, I.M. Grossi, J.D. Taylor and K. V. Honn. 1988. Role of tumor cell cytoskeleton and membrane glycoprotein IRGPIIb/IIIa in platelet adhesion to tumor cell membrane and tumor cell induced platelet aggregation. Cancer Res. 48:3787-3800.

70. Crissman, J.D., J.S. Hatfield, D.G. Menter, B.F. Sloane and K.V. Honn. 1988. Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res. 48: 4065-4072.

71. Honn, K.V., I.M. Grossi, L.A. Fitzgerald, L.A. Umbarger, C.A. Diglio and J.D. Taylor. 1988. Lipoxygenase products regulate IRGpIIb/IIIa receptor mediated adhesion of tumor cells to endothelial cells, subendothelial matrix and fibronectin. Proc. Soc. Exp. Biol. Med. 189:130-135.

72. Grossi, I.M., L.A. Fitzgerald, L.A. Umbarger, K.K. Nelson, C.A. Diglio, J.D. Taylor, and K.V. Honn. l989. Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res. 49:1029–l037.

73. Moin, K., J. Rozhin, T.B. McKernan, V.J. Sanders, D. Fong, K.V. Honn, and B.F. Sloane. 1989. Enhanced levels of cathepsin B mRNA in murine tumors. FEBS Letters. 244:61–64.

74. Onoda, J. M., K. K. Nelson, J. D. Taylor, and K.V. Honn. 1989. In Vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum (II)1. Cancer Res. 49:2844–2850.

75. Lah, T.T., M.R. Buck, K.V. Honn, J.D. Crissman, N.C. Rao, L.A. Liotta, and B.F. Sloane. 1989.    Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis. 7:461–468.

76. Rozhin, J., R.L. Wade, K.V. Honn, and B.F. Sloane.  1989. Membrane-associated cathepsin L. A role in metastasis of melanomas. Biochem Biophys Res. Commun. 164:556–561.

77. Honn, K.V., I.M. Grossi, C.A. Diglio, M. Wojtukiewicz and J.D. Taylor. 1989. Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE induced endothelial cell retraction. FASEB J. 3:2285–2293.

78. Lah, T.T., J.L. Clifford, K.M. Helmer, N.A. Day, K. Moin, J.D. Crissman, K.V. Honn, and B.F. Sloane. 1989. Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. Biochim Biophys Acta 993:63–73.

79. Onoda, J.M., K.K. Nelson, S.M. Pilarski, N.S. White, R.G. Mihu and K.V. Honn. 1990. Combination chemotherapy with cisplatin and nifedipine: Synergistic anti-tumor effects against a cisplatin-resistant subline of the B16 amelanotic melanoma. Clin. Exptl. Metastasis. 8:1, 59–73.

80. Rozhin, J., A.P. Gomez, G.H. Ziegler, K.K. Nelson, Y.S. Chang, D. Fong, J.M. Onoda, K.V. Honn, and B.F. Sloane. 1990. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res. 50:6278–6284.

81. Sloane, B.F., J. Rozhin, D. Robinson, and K.V. Honn. 1990. Role for Cathepsin B and Cystatins in Tumor Growth and Progression. Biol. Chem. Hoppe-Seyler. 371:193–198.

82. Chopra, H., S.E.G. Fligiel, J.S. Hatfield, K.K. Nelson, C.A. Diglio, J.D. Taylor, and K.V. Honn. 1990. An in Vivo Study of the Role of the Tumor Cell Cytoskeleton in Tumor Cell-Platelet-Endothelial Cell Interactions. Cancer Res. 50:7686–7696.

83. Chang, Y.S., Y.Q. Chen, L.A. Fitzgerald, K.V. Honn. 1991. Analysis of Integrin mRNA in Human and Rodent Tumor Cells. Biochem. Biophys. Res. Commun., 176:108–113.

84. Chelladurai, M., K.V. Honn, and D.A. Walz. 1991. HLA-DR is a Procoagulant. Biochem. Biophys. Res. Commun. 178:467–473.

85. Chopra, H., J. Timar, J.Q. Chen, X. Rong, I.M. Grossi, L.A. Fitzgerald, J.D. Taylor, and K.V. Honn.   1991. The Lipoxygenase Metabolite 12(S)-HETE Induces a Cytoskeleton-Dependent Increase in Surface Expression of Integrin aIIbb3 on Melanoma Cells. Intl. J. of Cancer, 49:774–786.

86. Liu, B., J. Timar, J. Howlett, C.A. Diglio, and K.V. Honn. 1991. Lipoxygenase Metabolites of Arachidonic and Linoleic Acids Modulate the Adhesion of Tumor Cells to Endothelium via Regulation of Protein Kinase C. Mol. Biol. Cell., 2:1045–1055.

87. Boike, G., T.T. Lah, B.F. Sloane, J. Rozhin, K.V. Honn, R. Guriguis, M.L. Stracke, L.A. Liotta, E. Schiffmann. 1991. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res. 1:333–340.

88. Chopra, H., J. Timar, X. Rong, R.M. Grossi, J.S. Hatfield, S.E.G. Fligiel, C.A. Finch, J.D. Taylor, and K.V. Honn. 1992. Is There a Role for the Tumor Cell Integrin aIIbb3 and Cytoskeleton in Tumor Cell-Platelet Interaction? Clin Exp. Metastasis, 10:125–137.

89. Buck, M.R., D.G. Karustis, N.A. Day, K.V. Honn, and B.F. Sloane. 1992. Degradation of Extracellular Matrix Proteins by Cathepsin B from Normal and Tumor Tissues. Biochem. J. 282:273–278.

90. Timar, J., H. Chopra, X. Rong, J.S. Hatfield, S.E.G. Fligiel, J.M. Onoda, J.D. Taylor, and K.V. Honn. 1992. Calcium Channel Blocker Treatment of Tumor Cells Induces Alterations in the Cytoskeleton, Mobility of the Integrin aIIbb3 Receptor and Tumor Cell-Induced Platelet Aggregation. J. Cancer Res. Clin. Oncol., 118:425–434.

91. Onoda, J.M., M.P. Piechocki, K.V. Honn. 1992. Radiation-Induced Increase in Melanoma Cell aIIbb3 Integrin Expression: Effects on Metastatic Potential. Radiation Res., 130:281–288.

92. Chang, Y.S., Y.Q. Chen, J. Timar, K.K. Nelson, I.M. Grossi, L.A. Fitzgerald, C.A. Diglio, and K.V. Honn. 1992. Increased Expression of aIIbb3 Integrin in High Lung Colonizing Subpopulations of Murine Melanoma Cells. Intl. J. Cancer, 51:445–451.

93. Liu, B., C. Renaud, K.K. Nelson, R. Bazaz, J. Kowynia, J. Timar, C.A. Diglio, and K.V. Honn. 1992. Protein Kinase C Inhibitor Calphostin C Reduces Melanoma Cell Adhesion to Endothelium and Lung Colonization. Intl. J. Cancer 52:147–152.

94. Honn, K.V., Y.Q. Chen, J. Timar, J.S. Hatfield, S.E.G. Fligiel, B.W. Steinert, C.A. Diglio, J.M. Onoda, I.M. Grossi, K.K.Nelson, and J.D. Taylor. 1992. aIIbb3 Integrin Expression and Function in Subpopulations of Murine Tumors. Exp. Cell Res. 201:23–32.

95. Chen, Y.Q., X. Gao, J. Timar, D. Tang, I. Grossi, M. Chelladurai, T.J. Kunicki, S.E.G. Fligiel, J.D. Taylor, and K.V. Honn. 1992 Identification of the aIIbb3 integrin in murine tumor cells. J. Biol Chem. 267:17314–17320.

96. Honn, K.V., Nelson, K.K., Renaud, C., Bazaz, R., Diglio, C.A., and Timar, J. 1992 Fatty Acid Modulation of Tumor Cell Adhesion to Microvessel Endothelium and Experimental Metastasis. Prostaglandins 44:413–429,

97. Timar, J., Y.Q. Chen, B. Liu, R. Bazaz, J.D. Taylor, and K.V. Honn. 1992. The lipoxygenase metabolite 12(S)-HETE promotes cytoadhesion aIIbb3 mediated tumor cell spreading on fibronectin. Intl. J. Cancer 52: 594–603.

98. Wojtukiewicz, M., Tang, D., Nelson, K.K., Walz, D., Diglio, C.A., and Honn, K.V. 1992 Thrombin Enhances Tumor Cell Adhesive and Metastatic Properties via Increased aIIbb3Expression on the Cell Surface. Thromb. Res. 68:233–245.

99. Tang, D.G., Y.Q. Chen, C. Renaud, C.A. Diglio, and K.V. Honn. 1993 Protein Kinase C-dependent Effects of 12(S)-HETE on Endothelial Cell Vitronectin Receptor and Fibronectin Receptor. J. Cell Biol. 121:689–704

100. Tang, D.G., C.A. Diglio, and K.V. Honn. 1993. 12(S)-HETE-Induced Microvascular Endothelial Cell Retraction Results from PKC-dependent Rearrangement of Cytoskeletal Elements and anb3 Integrins. Prostaglandins. 45:249–268

101. Steinert, B.W., D.G. Tang, C.L. Jones, I.M. Grossi, L.A. Umbarger, and K.V. Honn. 1993. Studies on the Role of Platelet Eicosanoid Metabolism and Integrin aIIbb3 in Tumor Cell Induced Platelet Aggregation. Intl. J. Cancer 54:92–101.

102. Tang, D.G., I.M. Grossi, Y.Q. Chen, C.A. Diglio, and K.V. Honn. 1993. 12(S)-HETE Promotes Tumor Cell Adhesion By Increasing Surface Expression of anb3 Integrins on Endothelial Cells. Intl. J. Cancer 54:102–111.

103. Tang, D.G., J.M. Onoda, B.W. Steinert, I.M. Grossi, K.K. Nelson, L. Umbarger, J.D. Taylor, and K.V. Honn. 1993. Phenotypic Properties of Cultured Tumor Cells: Integrin aIIbb3 Expression, Tumor Cell Induced Platelet Aggregation, and Tumor Cell Adhesion to Endothelium as Important Parameters of Experimental Metastasis. Intl. J. Cancer 54:338–347

104. Gao, X., K.V. Honn, D. Grignon and Y.Q. Chen. 1993. Frequent Loss of Expression and Loss of Heterozygosity of the Putative Tumor Suppressor Gene DCC in Prostatic Carcinomas. Cancer Res 53:2723–2727.

105. Tang, D.G., J. Timar, I.M. Grossi, C. Renaud, V.A. Kimler, C.A. Diglio, J.D. Taylor, and K.V. Honn. 1993. The Lipoxygenase Metabolite, 12(S)-HETE, Induces a Protein Kinase C Dependent Cytoskeletal Rearrangement and Retraction of Microvascular Endothelial Cells. Exp Cell Res. 207:361–375.

106. Timar, J., Tang, D., Bazaz, R., Kimler, V., Taylor, J.D., and Honn, K.V. 1993. PKC Mediates 12-(S)-HETE-Induced Cytoskeletal Rearrangement in B16a Melanoma Cells. Cell Motility & Cytoskeleton. 26:49–65.

107. Wojtukiewicz, M.Z., D.G. Tang, J.J. Ciarelli, K.K. Nelson, D.A. Walz, C.A. Diglio, E.F. Mammen, and K.V. Honn. 1993. Thrombin Increases the Metastatic Potential of Tumor Cells. Intl. J. Cancer 54:793–806.

108. Tang, D.G., Y.Q. Chen, P.J. Newman, L. Shi, X. Gao, C.A. Diglio, and K.V. Honn. 1993. Identification of PECAM-1 in Solid Tumor Cells and Its Potential Involvement in Tumor Cell Adhesion to Endothelium. J. Biol. Chem. 268:22883–22894.

109. Hagmann, W., Kagawa, D., Renaud, C. and K.V. Honn. 1993. Activity and protein distribution of 12-lipoxygenase in HEL cells: Induction of membrane-association by phorbol ester TPA, modulation of activity by glutathione and 13-HPODE, and Ca2+-dependent translocation to membranes. Prostaglandins. 46:471–477.

110. Timar, J., S. Silletti, R. Bazaz, A. Raz, and K.V. Honn. 1993. Regulation of Melanoma Cell Motility by the Lipoxygenase Metabolite 12(S)-HETE. Intl. J. Cancer. 55:1003–1010.

111. Honn, K.V., D.G. Tang, I.M. Grossi, Z.M. Duniec, J. Timar, C. Renaud, M. Leithauser, I. Blair, C.A. Diglio, J.D. Taylor, and L. J. Marnett. 1994. Tumor Cell-derived 12(S)-hydroxyeicosatetraenoic Acid Induces Microvascular Endothelial Cell Retraction. Cancer Res. 54:565–574.

112. Honn, K.V., D.G. Tang, I.M. Grossi, C. Renaud, and C.A. Diglio. 1994. Enhanced endothelial cell retraction mediated by 12(S)-HETE: A proposed mechanism for the role of platelets in tumor cell metastasis. Exp Cell Res. 210:1–9.

113. Tang, D.G., C.A. Diglio and K.V. Honn. 1994. Activation of Microvascular Endothelium by Eicosanoid 12(S)-HETE Leads to Enhanced Tumor Cell Adhesion via Upregulation of Surface Expression of avb3 Integrin: A Post-transcriptional, PKC- and Cytoskeleton-dependent Process. Cancer Res. 54:1119–1129.

114. Chen, Y.Q., Z.M. Duniec, B. Liu, X. Gao, W. Hagmann, L.J. Marnett, C.R. Johnson and K.V. Honn. 1994. Endogenous 12(S)-HETE Production by Tumor Cells and Its Role in Metastasis. Cancer Res. 54:1574–1579.

115. Liu, B., L.J. Marnett, A. Chaudhary, C. Ji, I.A. Blair, C.R. Johnson, C.A. Diglio, and K.V. Honn. 1994. Biosynthesis of 12(S)-hydroxyeicosatetraenoic acid by B16 Amelanotic Melanoma Cells is a Determinant of Their Metastatic Potential. Lab. Invest. 70:314–323.

116. Liu, B., R. J. Maher, Y. A. Hannun, A. T. Porter and K. V. Honn. 1994 12(S)-HETE Enhancement of Prostate Tumor Cell Invasion: Selective Role of PKCa. J. Natl. Cancer Inst. 86: 1145-1151.

117. Honn, K.V., Timar, J., Rozhin, J, Bazaz, R., Sameni, M., Ziegler, G., Taylor, J.D., and B.F. Sloane 1994 A Lipoxygnease Metabolite, 12(S)-HETE, Stimulates PKC-Mediated Release of Cathespin B from Malignant Cells. Exp Cell Res. 214: 120-130.

118. Gao, X., Ning, W., Grignon, D., Zacharek, A., Liu, H., Salkowski, A., Li, G., Sakr, W., Sarkar, F., Porter, A.T., Chen, Y.Q., and Honn, K.V. 1994 High Frequency of Mutator Phenotype in Human Prostatic Adenocarcinoma   Oncogene 9: 2999-3003.

119. Silletti, S., Timar, J., Honn, K.V., Raz, A. 1994 Autocrine Motility Factor Induces Differential 12-Lipoxygenase Expression and Activity in High and Low-Metastatic K1735 Melanoma Cell Variants. Cancer Res 54:5752-5756.

120. Onoda, J.M., Kantak, S., Piechocki, M.P., Awad, W., Chea, R., Liu, B. and Honn, K.V. 1994 Inhibition of Radiation Enhanced Expression of Integrin and Metastatic Potential in B16 Melanoma Cells by a Lipoxygenase Inhibitor. Radiation Res. 140: 410-418

121. Timar, J., Bazaz, R., Kimler, V., Haddad, M., Tang, D., Robertson, D., Tovari, J., Tarylor, J. and Honn, K. 1995 Immunomorphological characterization and effects of 12-(S)-HETE on a dynamic intracellular pool of the aIIbb3-integrin in melanoma cells. J. Cell Sci. 108: 2175-2186.

122. Gao, X., Ning, W., Grignon, D., Porter, A.T., Honn, K.V. 1995 Allelic Deletion of Microsatellite Loci on Chromosome 6p in a Subset of Human Prostate Cancer. Cancer Mol. Biol. J. 1:297-304

123. Gao, X., Zacharek, A., Grignon, D., Liu, H., Sakr, W., Porter, A., Chen, Y.Q., Honn, K.V. 1995 High Frequency of Loss of Expression and Allelic Deletion of the APC and MCC Genes in Human Prostate Cancer. Intl. J. Oncology 6:111-117

124. Tang, D., Grossi, M., Tang, K.Q., Diglio, C.A., Honn, K.V. 1995 Inhibition of TPA and 12(S)-HETE Stimulated Tumor Cell Adhesion by Prostacyclin and its Stable Analogs: Rationale for their Antimetastatic Effects. Intl. J. Cancer 55:698-704.

125. Wojtukiewicz, M.Z., Tang, D., Ben-Joszef, E., Renaud, C., Walz, D., Honn, K.V. 1995 Solid Tumor Cells Express Functional "Tethered-Ligand" Thrombin Receptor. Cancer Res 55:698-704.

126. Tang, D., Tarrien, M., Dobrzynski, P. and Honn, K. V. 1995 Melanoma Cell Spreading on Fibronectin Induced by 12(S)-HETE Involves Both Protein Kinase C- and Protein Tyrosine Kinase-Dependent Focal Adhesion Formation and Tyrosine Phosphorylation of Focal Adhesion Kinase (pp125FAK). J. Cellular Physiol. 165:291-306

127. Gao, X., Grignon, Chibihi, T., Zacharek, A., Chen, Y., Sakr, W. Porter, A., Crissman, Pontes, J., Powell, I. and Honn, K.V. 1995 Elevated 12-Lipoxygenase mRNA Expression Correlates with Advanced Stage and Poor Differentiation of Human Prostate Cancer. Urology 46:227-237, 1995.

128. Tang, D., Renaud, C., Stojakovic, S., Diglio, C., Porter, A. and Honn, K.V. 1995 12(S)-HETE Is a Mitogenic Factor for Microvascular Endothelial Cells: Its Potential Role in Angiogenesis. Biochem. Biophys. Res. Comm. 211: 462-468.

129. Gao, X., Chen, Y., Wu, N., Grignon, D., Sakr, W., Porter, A. and Honn, K.V. 1995 Somatic Mutations of the WAF1/CIP1 Gene in Primary Prostate Cancer Oncogene 11:1395-1398.

130. Gao, X., Zacharek, A., Grignon, D., Sakr., W., Powell, I., Porter, A. and Honn, K.V. 1995 Localization of Potential Tumor Suppressor Loci to a <2 Mb Region on Chromosome 17q in Human Prostate Cancer. Oncogene 11:1241-1247.

131. Liu, B., Khan, W., Hannun, Y., Timar, J., Taylor, J., Lundy, S., Butovich, I. and Honn, K.V.  1995 12(S)-Hydroxyeicosatetraenoic Acid and 13(S)-Hydroxyoctadecadienoic Acid Regulation of Protein Kinase C-a in Melanoma Cells: Role of Receptor-Mediated Hydrolysis of Inositol Phospholipids. Proc. Natl. Acad. Sci. 92: 9323-9327.

132. Hagmann, W., R. J. Maher, L.A. Wojciechowski, C. Renaud, and K.V. Honn. 1995 12-Lipoxygenase in Lewis Lung Tumor Cells: Intracellular Distribution of Activity and Protein, and Ca2+-Dependent Translocation from Cytosol to Membranes. Prostaglandins 49:49-62.

133. Chen, Y.Q., X. Gao, D. Grignon, F.H. Sarkar, W. Sakr, K.V. Honn, J.S. Borders, and J.D. Crissman. 1995 Multiple Mechanisms of p53 inactivation in Prostatic Carcinoma. Cancer Mol Biol J. 1:357-367.

134. Tang, D., Diglio, C.A., Honn, K.V. 1995 Transcriptional Activation of Endothelial Cell Integrin av by PKC Activator 12(S)-HETE. J. Cell Science. 108:2679-2644

135. Gao, X., Zacharek, A., Salkowski, A., Grignon, D., Sakr, W., Porter, A.T. and Honn, K.V. 1995 Loss of heterozygosity of the BRCA1 and Other Loci on Chromosome 17q in Human Prostate Cancer. Cancer Res. 55:1002-1005.

136. Timar, J., Trikha, M., Szekeres, K., Bazaz, R., Tovari, J., Silletti, S., Raz, A. and Honn, K. 1996   Autocrine Motility Factor Signals Integrin-Mediated Metastatic Melanoma Cell Adhesion and Invasion. Cancer Res 56:1902-1908.

137. Timar, J., Liu, B., Bazaz, R. and Honn, K.V 1996. Association of Protein Kinase C-a with Cytoplasmic Vesicles in Melanoma Cells. J Histochem Cytochem 44:177-182.

138. Tang, D., Chen, Y., Honn, K.V. 1996. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA. 93:5241-5246.

139. Tang, D.G., Diglio, C.A., Honn, K.V. 1996. Tyrosine Phosphorylation of a ~30kD Protein Precedes avb3 Integrin-signaled Endothelial Cell Spreading and Motility on Matrix Proteins. Path Oncol Res 2:21-29.

140. Hagmann, W., Gao, X., Timar, J., Chen, Y.Q., Strohmaier, A., Fahrenkopf, C., Kagawa, D., Lee, M., Zacharek, A., and Honn, K.V. 1996. 12-Lipoxygenase in A431 Cells: Genetic Identity, Modulation of Expression, and Intracellular Localization. Exp Cell Res 228:197-205

141. Trikha, M., Timar, J., Lundy, S.K., Szekeres, K., Tang, K., Grignon, D., Porter, A.T., and Honn, K.V. 1996. Human Prostate Carcinoma Cells Express Functional aIIbb3 Integrin¹.    Cancer Res 56:5071-5078.

142. Timar, J., Raso, E., Fazakas, Z., Silletti, S., Ras, A. and Honn, K.V. 1996. Multiple use of a signal transduction pathway in tumor cell invasion. Anticancer Res. 16:3299-3206.

143. Trikha, M., Timar, J., Lundy, S.K., Szekers, K., Cai, Yinlong, Porter, A.T. and K.V. Honn 1997. The High Affinity aIIbb3 integrin is involved in invasion of human melanoma cells. Cancer Research 57:2522-2528.

144. Tang, D., and Honn, K.V. 1997. Apoptosis of W256 Carcinosarcoma Cells of the Monocytoid Origin Induced by NDGA Involves Lipid Peroxidation and Depletion of GSH: Role of 12-Lipoxygenase in Regulating Tumor Cell Survival. J. Cell Physiol. 172:155-170.

145. Chen, Y.Q., Trikha, M., Gao, X., Bazaz, R., Porter, A.T., Timar, J., and Honn, K.V. 1997. Ectopic Expression of Platelet Integrin aIIbb3 in Tumor Cells from Various Species and Histological Origin. Int. J. Cancer 72: 642-648.

146. Tang, D.G., Guan, K-L., Li, L., Honn, K.V., Chen, Y.Q., Rice, R.L., Taylor, J.D., and Porter, A.T. 1997. Suppression of W256 Carcinosarcinoma Cell Apoptosis by Arachidonic Acid and Other Polyunsaturated Fatty Acids. Int. J. Cancer 72:1078-1087.

147. Trikha, M., Raso, E., Cai, Y., Fazakas, Z., Paku, S., Porter, A.J., Timar, J., and K.V. Honn. 1998. Role of aIIbb3 integrin in prostate cancer metastasis The Prostate 35:185-192.

148. Timar, J., Trikha, M., Szekeres, S., Bazaz, R., and Honn, K.V. 1998. Expression and function of the high affinity aIIb3 integrin in murine melanoma cells. Clin. Exp. Metastasis 16: 437-445.

149. Nie, D., Hillman, G.G., Geddes, T., Tang, K., Pierson, C., Grignon, D.J., and Honn, K.V. 1998. Platelet-Type 12-Lipoxygenase in a Human Prostate Carcinoma Stimulates Angiogenesis and Tumor Growth. Cancer Res. 58: 4047-4051.

150. Rice, R.L., Tang, D.G., Hadad, M., Honn, K.V. and Taylor, J.D. 1998. 12-(S)-hydroxyeicosatetraenoic acid increases the actin microfilament contents in B16a melanoma cells: A protein kinase-dependent process. Intl. J. Cancer: 77: 271-278.

151. Trikha, M., Cai, Y., Grignon, D. and Honn, K.V. 1998. Identification of a novel truncated aIIb integrin. Cancer Res. 58: 4771-4775.

152. Tang, D.G., Li, L., Zhu, Z., Joshi, B., Johnson, C.R., Marnett, L.J., Honn, K.V., Crissman, J.D., Timar, J., and Porter, A.T. 1998. BMD188, a novel hydroxamic acid compound demonstrates potent anti-prostate cancer effects in vitro and in vivo: Requirements for mitochondria, reactive oxygen species, and proteases. Pathol. Oncol. Res. 4(3):179-190.

153. Li L, Zhu Z, Joshi B, Zhang C, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Porter AT, and Tang DG. 1999. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies. Anticancer Res. 19(1A):61-69.

154. Tang, K., Nie, D., Cai, Y., and Honn, K.V. 1999. The b4 integrin subunit rescues A431 cells from apoptosis through a PI3K/Akt kinase signaling pathway. Biochem. and Biophys. Res. Comm: 264: 127-132.

156. Nie, D., Lamberti, M., Zacharek, A., Li, L., Szekeres, K., Tang, K., Chen, Y., and Honn, K.V. 2000. Thromboxane A₂ regulation of endothelial cell migration, angiogenesis and tumor metastasis. Biochem. Biophys. Res. Comm. 267: 245-251.

157. Tang, K., Finley R.L., Nie, D., and Honn, K.V. 2000. Identification of 12-Lipoxygenase Interaction with Cellular Proteins by Yeast Two-Hybrid Screening. Biochemistry. 39:3185-3191.

158. Szekeres, S. K., Trikha, M., Nie, D., and Honn, K.V., 2000. Eicosanoid 12(S)-HETE Activities Phosphatidylinositol 3-Kinase. Biochem. Biophys. Res. Comm. 275: 690-695.

159. Timar, J., Raso, E., Dome, B., Li, L., Grignon, D., Nie, D., Honn, K.V., and Hagmann, W. 2000. Expression, Subcellular Localization and Putative Function of Platelet-Type 12-Lipoxygenase in Human Prostate Cancer Cell Lines of Different Metastatic Potential. Int. J. Cancer. 87: 37-43.

160. Szekeres, S. K., Tang, K., Trikha, M., and Honn, K.V. 2000. Eicosanoid Activation of Extracellular Regulated Kinase 1/2 Activity in Human Epidermoid Carcinoma Cells. J. Biol. Chem. 275(49): 38831-38841.

161. Raso E., Tovari J., Toth K., Paku S., Trikha M., Honn K.V., and Timar J. 2001. Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells. Thromb. Haemost.   85(6):1037-1042.

162. Tang, X., Xian, M., Trikha, M., Honn, K.V., and Wang, P.G. 2001 Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents. Tetrahedron Letters, 42 (14):. 2625 – 2629.

163. Pidgeon, G.P., Kandouz, M., Meram, A., and Honn, K.V. 2002. Mechanisms controlling cell cycle arrest and induction of apoptosis following 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res.  62(9):2721-7.

164. Trikha, M., Timar, J., Zachaarek, A., Nemeth, J.A., Cai, Y., Dome, B., Somlai, B., Raso, E., Ladanyi, A., and Honn, K.V. 2002    Role for ß3 integrins in human melanoma growth and survival.   Int. J. Cancer, 101(2):156-67.

165. Pidgeon, G.P., Tang, K., Rice, R.L., Zacharek, A., Li, L., Taylor, J.D., and Honn, K.V. 2003 Overexpression of Leukocyte-Type 12-Lipoxygenase Promotes W256 Tumor Cell Survival by enhancing aVb5 expression. Int. J. Cancer. 105:459-471.

166. Pidgeon, G.P., Tang, K., Cai, Y., Piasentin, E., and Honn, K.V. 2003. Over-expression of Platelet-type 12 Lipoxygenase Promotes Tumor Cell Survival by alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res. 63(14):4258-4267.

167. Kandouz, M., Nie, D., Pidgeon, G. P., Krishnamoorthy, S., Maddipati, K., and Honn, K.V. 2003. Platelet-type 12-Lipoxygenase Activates NF-B in Prostate Cancer Cells. Prostaglandins and Other Lipid Mediators 71:189-204.

168. Nie, D., Nemeth, J. Qiao, Y., Zacharek, A., Li, L., Hanna, K., Tang, K., Hillman, G.G., Cher, M., Grignon, D.J., and Honn, K.V.   2003   Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.   Clinical and Experimental Metastasis 20:657-663.

169. Nie, D., Che, M., Zacharek, A., Qiao, Y., Li, L., Li, X., Lamberti ,M., Tang, K., Cai, Y., Guo, Y., Grignon, D., Honn, K.V. 2004.   Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol.    164(2): 429-39.

170. Raso E, Dome B, Somlai B, Zacharek A, Hagmann W, Honn KV, Timar J. 2004. Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Res. 14(4):245-50.

171. Dome B, Raso E, Dobos J, Meszaros L, Varga N, Puskas LG, Feher LZ, Lorincz T, Ladanyi A, Trikha M, Honn KV, Timar J. 2005   Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype. Int J Cancer 116(1):27-35.

172.   Nie D, Krishnamoorthy S, Jin R, Tang K, Chen Y, Qiao Y, Zacharek A, Guo Y, Milanini J, Page G,     Honn KV. 2006 Mechanisms Regulating Tumor Angiogenesis by 12-Lipoxygenase in Prostate Cancer Cells. Journal Biological Chemistry 281(27):18601-18609

173. Jin R, Trikha M, Cai Y, Grignon, D, and Honn, KV.; 2007. A naturally occurring truncated beta 3 integrin in tumor cells: native anti-integrin involved in tumor cell motility. Cancer Biol Ther; 6:1559-68

174. Nie D, Guo Y, Yang D, Tang Y, Chen Y, Wang W, Zacharek A, Qiao Y, Che M, and Honn KV., 2008. Thromboxane A2 Receptor in Prostate Carcinoma: Expression and its Role in Regulating Cell Motility via Small GTPase Rho. Cancer Res.; 68:115-21

   175. Tao, XH, Shen JG, Pan WL, Dong YE, Menq Q, Honn KV, Jin R., 2008. Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma Acuminatum and Cervical Cancer. Pathol Oncol Res. 14:365-371

Tang Y, Wang MT, Chen Y, Yang D, Che M, Honn KV, Akers GD, Johnston SR, Nie, D. Downregulation of Vascular Endothelial Growth Factor and Induction of Tumor Dormancy by 15-lipoxygenase-2 in Prostate Cancer. Intl J. Cancer

1.       Tang, K., Nie, D., Finley Jr., R.L., Cai, Y., Lamberti, M., Fridman, R., Carey, T.E., Crissman, J.D., and Honn, K.V. Regulation Of Arachidonate Platelet Type 12-Lipoxygenase By Physical Interaction With The Integrin b4 Subunit.

2.       Sriram Krishnamoorthy, Rongxian Jin, Yinlong Cai, Krishna Rao Maddipati, Gilles Pages, and Kenneth V. Honn, 2007; Regulation Of Hypoxia Inducible Factor-1 In A Normoxic Microenvironment By 12-Lipoxygenase In Prostate Cancer.

3.       Sriram Krishnamoorthy, Rongxian Jin, Yinlong Cai, Krishna Rao Maddipati, Gilles Pages, and Kenneth V. Honn, 2007; 12-Lipoxygenase And The Regulation Of Hypoxia Inducible Factor-1 In Prostate Cancer.

 4.   Tang K, Nie D, Cai Y, Repaskey W, Joshi S, Tucker SC, Fridman R, Crissman JD, Honn KV.     Regulation of Arachidonate 12-Lipoxygenase by Physical Interaction with the Integrin B4 Subunit. Journal Biological Chemistry 2008 (submitted)

5.       Krishnamoorthy S, Jin R, Cai Y, Maddipati KR, Nie D, Pages G, Honn KV. 12-Lipoxygenase and the Regulation of Hypoxia Induced Angiongenesis in Prostate Cancer. Journal Biological Chemistry 2008 (currently in review).

1. Honn, K.V., R.S. Bockman, and L.J. Marnett. 1981. Prostaglandins and cancer: A review of tumor initiation through tumor metastasis. Prostaglandins. 21:833–864.

2. Honn, K.V., W.D. Busse, and B.F. Sloane. 1983. Prostacyclin and thromboxanes: Implications for their role in tumor cell metastasis. Biochem. Pharmacol. 32:1–11.

3. Honn, K.V., D. Menter, P.G. Cavanaugh, G. Neagos, D. Moilanen, J.D. Taylor, and B.F. Sloane. 1983. A review of prostaglandins and the treatment of tumor metastasis. ACTA Clinic Belgica 38:53–67.

4. Honn, K.V., D.G. Menter, J.M. Onoda, J.D. Taylor, and B.F. Sloane. 1983. Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis. Symp. Fundam. Cancer Res. 36:361–388.

5. Sloane, B.F. and K.V. Honn. 1984. Cysteine proteinases and metastasis. Cancer & Metastasis Rev. 3:249–265.

6. Sloane, B.F., J. Rozhin, J.S. Hatfield, J.D. Crissman, and K.V. Honn. 1987. Plasma membrane- associated cysteine proteinases in human and animal tumors. Exp. Cell Biol. 55:209–224.

7. Weiss, L., F.W. Orr, and K.V. Honn. 1988. Interactions of cancer cells with the microvasculature during metastasis. FASEB J. 2:12–21.

8. Weiss, L., F.W. Orr and K.V. Honn. 1989. Interactions between cancer cells and the microvasculature: A rate-regulator for metastasis. Clin. Exp. Metastasis. 7:127–167.

9. Honn, K.V., D.G. Tang, and Y.Q. Chen. 1992. Platelets and Cancer Metastasis: More than an Epiphenomenon. Seminars Thromb Hemost. 18:390–413.

10. Honn, K.V. and D.G. Tang. Adhesion Molecules and Cancer Cell Interaction with Endothelium and Subendothelial Matrix. 1992. Cancer Metastasis Rev 11:353–375.

11. Honn, K.V., D.G. Tang, and J.D. Crissman. Platelets and Cancer Metastasis: A Causal Relationship? 1992. Cancer Metastasis Rev 11:325–351.

12. Chen, Y.Q., B. Liu, D.G. Tang, and K.V. Honn. Fatty Acid Modulation of Tumor Cell-Platelet-Vessel Wall Interaction. 1992. Cancer Metastasis Rev 11:389–410.

13. Honn, K.V. and D. Tang. Hemostasis and Malignancy: An Overview. 1992 Cancer Metastasis Rev 11:223–226.

14. Honn, K.V. and D. Tang. Commentary: The Kohn and Liotta Article Reviewed . Invasion and Metastasis: An old problem with new approaches. 1993 Oncology 7:61–62.

15. Marnett, L.J., Honn, K.V. Overview of Articles on Eicosaniods and Cancer. 1994 Cancer Metastasis Rev. 13: 237-240.

16. Honn, K.V., Tang, D.G., Gao, X., Butovich, I., Liu, B., Timar, J., Hagmann, W. 12-Lipoxygenase and 12(S)-HETE: Role in Cancer Metastasis. 1994 Cancer Metastasis Rev. 13:365-396.

17. Schneider, M.R., Tang, D.G., Schiner, M., Honn, K.V. Prostacyclin and Its Analogues: Antimetastatic Effects and Mechanisms of Action. 1994 Cancer Metastasis Rev. 13: 365-396

18. Tang, D.G. and Honn, K.V. 12-Lipoxygenase, 12(S)-HETE and Cancer Metastasis. 1994 Ann. N.Y. Acad. Sci. 744: 199-215

19. Gao, X. and Honn, K. V. Role of Fatty Acids in Cancer Metastasis and Gene Regulation. 1994 Cancer Mol Bio J. 1:345-356.

20. Gao, X. and Honn, K.V. 1995 12-Lipoxygenase and 12(S)-HETE in Cancer Invasion and Metastasis.   Adv. Oncology 11(2):3-8.

21. Gao, X. and Honn, K.V. 1995 12-Lipoxygenase as a Prostate Cancer Marker and Therapeutic Target Adv. Oncology 11:2-8

22. Tang, D., and Honn, K.V. Adhesion Molecules and Tumor Metastasis: An Update. 1995 Invasion & Metastasis. 14:109-122.

23. Gao, X., Porter, A.T., and Honn, K.V. 1995 Tumor Suppressor Genes and their Involvement in Human Prostate Cancer, Cancer Mol. Biol. J. 2:475-498.

24. Gao, X.and Honn, K. 1995 Recessive Oncogenes: Current Status. Path. Oncol. Res. 1:1-7.

25. Honn, K.V., Aref, A., Chen, Y.Q., Cher, M.L., Crissman, J.D., Foreman, J.D., Gao, X., Grignon, Hussain, M., Porter, A.T., Pontes, J.E., Powell, I., Redman, B., Sakr. W., Severson, R., Tang, D., Wood, D.P.   1996 Prostate Cancer - Old Problem and new Approaches. Part I. Epidemiology, Incidence and Genetic Alterations. Path. Oncol. Res. 2:98-109.

26. Honn, K.V., Aref, A., Chen, Y.Q., Cher, M.L., Crissman, J.D., Foreman, J.D., Gao, X., Grignon, D. Hussain, M., , M., Porter, A.T., Pontes, J.E., Powell, I., Redman, B., Sakr. W., Severson, R., Tang, D.G., Wood, D.P.   1996 Prostate Cancer - Old Problems and New Approaches.   Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects. Path. Oncol. Res. 2:191-211.

27. Honn, K.V., Aref, A., Chen, Y.Q., Cher, M.L., Crissman, J.D., Foreman, J.D., Gao, X., Grignon, D. Hussain, M., , M., Porter, A.T., Pontes, J.E., Powell, I., Redman, B., Sakr. W., Severson, R., Tang, D., Wood, D.P.   1996 Prostate Cancer - Old Problems and New Approaches. Part III. Prevention and Treatment. Path. Oncol. Res. 2:276-292.

28. Gao, X., Porter, A.T., Grignon, D.J., Pontes, J.E., and Honn, K.V. 1997 Diagnostic and Prognostic Markers for Human Prostate Cancer. The Prostate 31:264-281.

29. Nie, D., Tang, K., Szekeres, K., Trikha, M., and Honn, K.V. 2000.   The Role of Eicosanoids in Tumor Grown and Metastasis.    Ernst Schering Research Foundation Workshop: (31):201-17.

30. Nie, D., Tang, K. Szekeres, K., Li, L. and Honn, K.V. Eicosanoid Regulation of Angiogenesis in Human Prostate Carcinoma and Its Therapeutic Implications. Annals N.Y. Acad. Science. 905:165-76.

31. Nie, D., Che, M., Grignon, D., Tang, K., and Honn, K.V. 2001 Role Of Eicosanoids In Prostate Cancer Progression. Cancer and Metastasis Rev. 20:195-206.

32. Nie, D., and Honn, K.V. 2002   Cyclooxygenase, Lipoxygenase and Tumor Angiogenesis. Cell. Mol. Life Sci.    59(5):799-807.

33. Nie, D., and Honn, K.V.   2004 Eicosanoid Regulation of Angiogenesis in Tumors. Semin.   Thromb. Hemost. 30(1):119-25.

34.   Krishnamoorthy, S. and Honn, K.V. 2006 Inflammation and disease progression. Cancer Metastasis Reviews. 25(3):481-491

35.   Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007; 26:525-34.

36.   Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O’byrne K, Nie D, Honn KV. Lipoxygenase metabolism: role in tumor progression and survival. Cancer Metastasis Rev. 2007; 26:503-24

37.   Krishnamoorthy S, Honn KV. Eicosanoids in Tumor Progression and Metastasis.   Subcellular Biochemistry 2008; 49:145-68

1.      Powles, T.J., R.S. Bockman, K.V. Honn, and P.W. Ramwell. (eds.) 1982. Prostaglandins & Cancer. Alan Liss, Inc., New York, 841 pp.

2.      Honn, K.V. and B.F. Sloane. (eds.) 1984. Hemostatic Mechanisms and Metastasis. Martinus Nijhoff, The Hague, 433 pp.

3.      Honn, K.V., W.E. Powers, and B.F. Sloane. (eds.) 1986. Mechanisms of Cancer Metastasis: Potential Therapeutic Implications. Martinus Nijhoff, The Hague, 423 pp.

4.      Honn, K.V., L.J. Marnett, S. Nigam, T. Walden., (eds.) 1991. Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Kluwer Academic Publishers, Boston. 515 pp.

5.      Nigam, S., K.V. Honn, L.J. Marnett, and T. Walden, (eds.) 1992. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Kluwer Academic Publishers, Boston. 799 pp.

6.      Honn, K.V., S. Nigam, and L.J. Marnett (eds.) 1997. Part A. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Volume 400A. Advances in Experimental Medicine and Biology, Plenum Press, New York, 555 pp.

7.      Honn, K.V., S. Nigam, and L.J. Marnett (eds.) 1997. Part B. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Volume 400B. Advances in Experimental Medicine and Biology, Plenum Press, New York, 515 pp.                                  

8.      Honn, K.V., Nigam, S., Marnett, L.J., Jones, R.L. and Wong, P. Y-K., (eds.) 1997. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Radiation Injury Part 3. Advances in Experimental Medicine and Biology, Volume 407. Plenum Press, New York, 599 pp.

9.             Honn K.V., Dennis, E., Nigam, S., and Marnett, J.J., (eds.) 1999. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Related Diseases. Part 4. Advances in Experimental Medicine and Biology. Plenum Press, New York, 699 pp.

10.         Wood, D.P. and Honn, K.V (eds.). 1999. Advances in Oncobiology, Vol. 3. JAI Press, Greenwich, 264 pp.

11.     Honn, K.V., Marnett, L.J., Nigam, S, Serhan, C., eds 2002. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases 5. Advances in Experimental Medicine and Biology. Plenum Press, New York, 597 pp..

12.     Cher, M., Honn, K.V., and Raz, A. (eds) 2002 Prostate Cancer. New Horizons Research and Treatment. Kluwer Press, New York, 399 pp

"Prostaglandins, Leukotrienes, and Cancer". K.V. Honn and L.J. Marnett (series editors). Martinus Nijhoff, The Hague.

·         Vol. 1. "Biochemistry of Arachidonic Acid Metabolism" (W.E. Lands, ed.) 1985 442 pp.

·         Vol. 2. "Arachidonic Acid Metabolism and Tumor Initiation" (L.J. Marnett ed.)1985 200 pp.

·         Vol. 3. "Arachidonic Acid Metabolism and Tumor Promotion" (S. Fisher and T. Slaga,      eds.) 1985 263 pp.

·         Vol. 4. "Prostaglandins and Immunity" (J. Goodwin, ed.) 1985 209 pp.

·         Vol. 5. "Ecosanoids and Radiation Damage" (P. Polgar, ed.) 1988 198 pp.

·         Vol. 6. "Carcinogenesis and Dietary Fat" (S. Abraham, ed.) 1989, 492 pp.

G. Invited Book Chapters and Proceedings of Symposia

1. Honn, K.V. and Chavin, W. (1980). Mechanism of action of some polypeptide hormones in an evolutionary series of vertebrates. In: Evolution of Vertebrate Endocrines, (P. Pang and A. Epple, eds.), Texas Tech Press, Lubbock, Texas, 133-166.

2. Menter, D., Neagos, G., Dunn, J., Palazzo, R., Tchen, T.T., Taylor, J.D. and Honn, K.V. (1982). Tumor cell induced platelet aggregation: Inhibition byprostacyclin, thromboxane A2 and phosphodiesterase inhibitors. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn, and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 809-814.

3. Turner, W.A., Taylor, J.D. and Honn, K.V. (1982). Effects of prostaglandin "A" series on tumor cells in vitro. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn, and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 369-374.

4. Turner, W.A., Bennett, D.R., Thompson, K.C., Taylor, J.D. and Honn, K.V. (1982). Structural activity requirement for PGA effects on tumor cell growth and differentiation. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn, and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 365-368.

5. Sloane, B.F., Makim, S., Dunn, J.R., Lacoste, R., Theodoreau, M., Battista, J., Alex, R. and Honn, K.V. (1982). Lipoxygenase products as mediators of tumor cell lysosomal enzyme release: Inhibition by nafazatrom. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn, and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 789-792.

6. Eling, T.E., Honn, K.V., Busse, W., Seuter, F. and Marnett, L.J. (1982). Stimulation of PGI2 biosynthesis by nafazatrom (Bay g 6575). In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 783-788.

7. Honn, K.V., Dunn, J.R. and Meyer, J. (1982). Thromboxanes and prostacyclin: Positive and negative modulators of tumor cell proliferations. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 375-380.

8. Honn, K.V. (1982). Prostacyclin/thromboxane ratios in tumor growth and metastasis. In: Prostaglandins and Cancer, (T.J. Powles, R.S. Bockman, K.V. Honn and P.W. Ramwell, eds.), Alan Liss, Inc., New York, 733-752.

9. Honn, K.V., Meyer, J., Neagos, G., Henderson, T., Westley, C. and Ratanatharathorn, V. (1982). Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: Evidence for a new anti-tumor and anti-metastatic agent (Bay g 6575). In: Interactions of Platelets and Tumor Cells, (G.A. Jamieson, ed.), Alan Liss, Inc., New York, 295-331.

10. Honn, K.V. and Sloane, B.F. (1983). Prostacyclin, thromboxanes and hematogenous metastasis. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Volume 12, (B. Samuelsson, R. Paoletti and P. Ramwell, eds.), Raven Press, New York, 313-318.

11. Honn, K.V., Menter, D., Moilanen, D., Cavanaugh, P.G., Taylor, J.D. and Sloane, B.F. (1983). Role of prostacyclin and thromboxanes in tumor cell-platelet-vessel wall interactions. In: Protective Agents in Cancer, (D.C.H. McBrien and T.F. Slater, eds.), Academic Press, New York, 57-79.

12. Honn, K.V., Menter, D.G., Onoda, J.M., Taylor, J.D. and Sloane, B.F. (1984). Role of prostacyclin and a natural deterrent to hematogenous tumor metastasis. In: Cancer Invasion and Metastasis, (G. Nicolson and L. Milas, eds.), Raven Press, New York, 361-388.

13. Onoda, J.M., Sloane, B.F., Taylor, J.D. and Honn, K.V. (1984). Calcium channel blockers: Inhibitors of tumor cell-platelet-endothelial cell interactions. In: Hemostatic Mechanisms and Metastasis, (K.V. Honn and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 244-258.

14. Honn, K.V., Onoda, J.M., Menter, D.G., Taylor, J.D. and Sloane, B.F. (1984). Prostacyclin/thromboxanes and tumor cell metastasis. In: Hemostatic Mechanisms and Metastasis, (K.V. Honn and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 207-231.

15. Sloane, B.F., Cavanaugh, P.G. and Honn, K.V. (1984). Tumor cysteine proteinases, platelet aggregation and metastasis. In: Hemostatic Mechanisms and Metastasis, (K.V. Honn and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 170-191.

16. Honn, K.V. and Marnett, L.J. (1984). Prostaglandins, thromboxanes and leukotriene biosyntheses: Target for antitumor and antimetastatic agents. In: Novel Approaches to Cancer Chemotherapy, (P. Sunkara, ed.), Academic Press, New York, 127-163.

17. Honn, K.V. and Sloane, B.F. (1985). Prostaglandins in tumor cell metastasis. In: Basic Mechanisms and Clinical Treatments of Tumor Metastasis, (M. Torisu and Y. Yoshida, eds.),   Academic Press, New York, 311-334.

18. Sloane, B.F. and Honn, K.V. (1985). Proteolytic enzymes and arachidonic acid metabolism. Basic Biochemical Processes, (W.E. Lands, ed.). Vol. 1. In: Prostaglandins, Leukotrienes, and Cancer, (K.V. Honn and L.J. Marnett, series eds.), Martinus Nijhoff, The Hague, 311-321.

19. Sloane, B.F., Rozhin, J., Crissman, J.D. and Honn, K.V. (1985). Association of a cathepsin B-like cysteine proteinase with tumor cell plasma membranes. In: Treatment of Metastasis: Problems and Prospects, (K. Hellmann and S. Eccles, eds.), Taylor and Francis, London, 377-380.

20. Honn, K.V., Onoda, J.M.,Taylor, J.D. and Sloane, B.F. (1985). Antimetastatic therapy with calcium active compounds. In: Treatment of Metastasis: Problems and Prospects, (K. Hellman and S. Eccles, eds.), pp. 259–262. Taylor and Francis, London.

21. Onoda, J.M., Sloane, B.F. and Honn, K.V. (1985). Antimetastatic therapy with thromboxane synthase inhibitors. In: Treatment of Metastasis: Problems and Prospects, (K. Hellman and S. Eccles, eds.), Taylor and Francis, London, 263-266.

22. Crissman, J.D., Honn, K.V. and Sloane, B.F. (1985). Metastasis from metastasis: An animal model. In: Treatment of Metastasis: Problems and Prospects, (K. Hellman and S. Eccles, eds.), Taylor and Francis, London, 211-214.

23. Honn, K.V., Onoda, J.M., Menter, D.G., Taylor, J.D. and Sloane, B.F. (1985). Prostacyclin in the control of tumor metastasis. In: Biological Protection with Prostaglandins, Volume 1, (M.M. Cohen, ed.), CRC Press, Florida, 91-110.

24. Marnett, L.J. and Honn, K.V. (1985). Chemical mechanisms of modulation of tumor growth and metastasis by prostaglandins. In: Mechanisms of Metastasis:  Potential Therapeutic Implications, (K.V. Honn, W.E. Powers and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 103-118.

25. Sloane, B.F., Rozhin, J., Ryan, R.E., Lah, T.T., Day, N.A., Crissman, J.D. and Honn, K.V. (1985). Cathepsin B-like cysteine proteinases and metastasis. In: Mechanisms of Metastasis: Potential Therapeutic Implications, (K.V. Honn, W.E. Powers and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 377–398.

26. Honn, K.V., Onoda, J.M., Menter, D.G., Cavanaugh, P.G., Crissman, J.D., Taylor, J.D. and Sloane, B.F. (1985). Platelet tumor cell interactions as a target for antimetastatic therapy. In: Mechanisms of Cancer Metastasis: Potential Therapeutic Implications, (K.V. Honn, W.E. Powers and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 118–144.

27. Crissman, J.D. and Honn, K.V. (1985). Applications for antimetastatic therapies. In: Mechanisms of Metastasis: Potential Therapeutic Implications, (K.V. Honn, W.E. Powers and B.F. Sloane, eds.), Martinus Nijhoff, The Hague, 399-417.

28. Honn, K.V., Weller, P. and Marnett, L.J. (1985). Effects of prostaglandins possessing an a,ß unsaturated carbonyl on tumor growth and differentiation. In: Proceedings of the Kyoto Conference on Prostaglandins, Volume 15, (S. Yamamoto, ed.). Vol. 15, Raven Press, New York, 411-413.

29. Honn, K.V., Onoda, J.M., Menter, D.G., Cavanaugh, P.G., Taylor, J.D., Crissman, J.D., Ryan, R.E., and Sloane, B.F. (1986). Possible strategies for antimetastatic therapy. In: Cancer Metastasis: Experimental and Clinical Strategies, (D.R. Welch, B.K. Bhuyan and L. Liotta, eds.), Alan R. Liss, New York, 217-246.

30. Crissman, J.D., Hatfield, J.S. and Honn, K.V. (1986). Clinical and experimental morphologic parameters predictive of tumor metastasis. In: Cancer Metastasis: Experimental and Clinical Strategies, (D.R. Welch, B.K. Bhuyan and L. Liotta, eds.), Alan R. Liss, New York, 251-265.

31. Sloane, B.F., Ryan, R.E. , Rozhin, J., Lah, T.T., Crissman, J.D. and Honn, K.V. (1986). Cathepsin B: A proteinase linked to metastasis? In: Proteinases in Inflammation and Tumor Invasion, (H. Tschesche, ed.), Walter de Gruyter & Co., Berlin, 93-106.

32. Honn, K.V., Menter, D.G., Steinert, B.W., Taylor, J.D., Onoda, J.M. and Sloane, B.F. (1987). Analysis of platelet, tumor cell, and endothelial cell interactions in vivo and in vitro. In: Prostaglandins in Cancer Research, (E. Garaci, R. Paoletti, and M.G. Santoro, eds.), Springer-Verlag, Berlin, 172–183.

33. Dunn, J.R. II, Ohannesian, D.W., Tefend, S., Malik, D., Kendall, A., Taylor, J.D., Sloane, B.F. and Honn, K.V. (1987). The effects of eicosanoid inhibitors on tumor cell arachidonic acid (and metabolite) uptake, release and metabolism. In: Prostaglandins in Cancer Research, (E. Garaci, R. Paoletti and M.G. Santaro, eds.), Springer-Verlag, Berlin, 257–261.

34. Honn, K.V., Menter, D.G., Onoda, J.M., Steinert, B.W., Diglio, C.A., Taylor, J.D. and Sloane, B.F. (1987). Tumor cell-platelet-endothelial interactions and prostaglandin metabolism. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Volume 17B, (B. Samuelsson, R. Paoletti, P. Ramwell, eds.), Raven Press, New York, 981–985.

35. Sloane, B.F., Lah, T.T., Day, N.A., Rozhin, J. and Honn, K.V. (1987). Tumor cysteine proteinases and their inhibitors. In: Cysteine Proteinases and Their Inhibitors, (V.Turk, ed.), Walter de Gruyter & Co., Berlin, 729–749.

36. Steinert, B.W., Sloane, B.F., Menter, D.G., Crissman, J.D., Taylor, J.D. and Honn, K.V. (1988). Role of eicosanoids in tumor cell-platelet-endothelial cell interactions. In: Anticarcinogenesis and Radiation Protection, (O.F. Nygaard, M. Simic, and P. Cerutti, eds.), Raven Press, New York, 63–69.

37. Sloane, B. F., Rozhin, J., Lah, T.T., Day, N.A., Buck, M., Ryan, R.E., Crissman, J.D. and Honn, K.V. (1988). Tumor cathepsin B and its endogenous inhibitors in metastasis. In: Cancer Metastasis. Biological and Biochemical Mechanisms and Clinical Aspects, (G.Prodi, L.A. Liotta, P.L. Lollini, S. Garbisa, S. Gorini and K. Hellman, eds.), Plenum Press, New York, 259–268.

38. Sloane, B. F., Rozhin, J., Lah, T.T., Day, N.A., Buck, M., Ryan, R.E., Crissman, J.D. and Honn, K. V. (1988). Tumor cathepsin B and its endogenous inhibitors in metastasis. In: Cancer Metastasis Biological and Biochemical Mechanisms and Clinical Aspects, (G. Prodi, L. A. Liotta, P. L. Lollini, S. Garbisa, S. Gorini, and K. Hellmann, eds.), Plenum Press, New York and London, 259–268.

39. Honn, K.V., Grossi, I.M., Chopra, H., Steinert, B.W., Onoda, J.M., Nelson, K.K. and Taylor, J.D. (1988). Role of tumor cell eicosanoids and membrane glycoproteins IRGp Ib and IRGp IIb/IIIa in metastasis. In: Eicosanoids, Lipid Peroxidation and Cancer, (S. Nigam, D.C.H. Mc Brien and T.F. Slater, eds.), Springer Verlag, Berlin, 29-42.

40. Honn, K.V., Grossi, I.M., Steinert, B.W., Chopra, H., Onoda, J. M., Nelson, K.K. and Taylor, J. D. (1989). Lipoxygenase Regulation of Membrane Expression of Tumor Cell Glycoproteins and Subsequent Metastasis. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research, Volume 19, (P. Wong, B. Samuelsson, and F. Sun, eds.), Raven Press, New York, pp. 439–443.

41. Honn, K.V., Grossi, I.M., Diglio, C.A. and Taylor, J.D. (1990). Role of 12-lipoxygenase metabolites and integrin glycoprotein receptors in metastasis. In: New Concepts in Cancer Treatment, (C. Etievant, J. Cros, and Y.M. Rustum, eds.), McMillan Press Ltd., London, 42-62.

42. Marnett, L.J., Leithauser, M.T., Richards, K.M., Blair, I., Honn, K.V., Yamamoto, S. and Yoshimoto, T. (1990). Arachidonic acid metabolism of cytosolic fractions of Lewis lung carcinoma cells. In: Advances in Prostaglandin Thromboxane and Leukotriene Research, Volume 21, (B. Samuelsson, P. Ramwell, R. Paoletti, G. Folco, and E. Granstrom, eds.), Raven Press, New York, 895-900.

43. Honn, K.V., Grossi, I.M. , Timar, J., Chopra, H. and Taylor, J.D. (1991). Platelets and cancer metastasis. In: Microcirculation in Cancer Metastasis, (W. Orr, M. Buchanan, and L. Weiss, eds.), CRC Press, Inc., Boca Raton, Florida, 93-110.

44. Honn, K.V., Grossi, I.M., Chang, Y.S. and Chen, Y. (1991). Lipoxygenases, integrin receptors, and metastasis. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury, (K.V. Honn, L.J. Marnett, S. Nigam, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 321-330.

45. Timar, J., Chopra, H., Grossi, I.M., Taylor, J.D. and Honn, K.V. (1991). The lipoxygenase metabolite of arachidonic acid, 12-(S)-HETE, induces cytoskeleton dependent upregulation of integrin aIIbb3 in melanoma cells. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury, (K.V. Honn, L.J. Marnett, S. Nigam, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 331-346.

46. Sloane, B.F., Rozhin, J., Gomez, A.P., Grossi, I.M. and Honn, K.V. (1991). Effects of 12-hydroxyeicosatetraenoic acid on release of cathepsin B and cysteine proteinase inhibitors from malignant melanoma cells. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury, (K.V. Honn, L.J. Marnett, S. Nigam, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 373-378.

47. Grossi, I.M., Diglio, C.A. and Honn, K.V. (1991). Control of tumor cell induced endothelial cell retraction by lipoxygenase metabolites, prostacyclin, and prostacyclin analogues. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury, (K.V. Honn, L.J. Marnett, S. Nigam, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 409-414.

48. Raz, A., Silletti, S., Timar, J. and Honn, K.V.  (1992). Effect of 12-HETE on the expression of autocrine motility factor-receptor and motility in melanoma cells. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 645-649.

49. Tang, D.G., Diglio, C.A. and Honn, K.V. (1992). 12(S)-HETE-induced microvascular endothelial cell retraction is mediated by cytoskeletal rearrangement dependent on PKC activation. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 219-229.

50. Jones, C.L. and Honn, K.V. (1992). Enhanced membrane expression of cytoadhesin aIIbb3in Lewis lung carcinoma cells by epoxyeicosatrienoic acids. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 671-678.

51. Chen, Y.Q. and Honn, K.V. (1992). Eicosanoid regulation of tumor cell-platelet and -endothelium interaction during arrest and extravasation. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 613-617.

52. Onoda, J.M., Piechocki, M.P., Kantak, S., Nelson, K.K., Mamytbekova, A.Z. and Honn, K.V. (1992). Radiation enhances tumor cell metastasis. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T. Walden, eds.), Kluwer Academic Publishers, Boston, 683-687.

53. Liu, B., Renaud, C., Kowynia, J., Nelson, K.K., Roudachevski, E., Snyder, D., Timar, J. and Honn, K.V. (1992). Activation of protein kinase C by 12(S)-HETE: Role in tumor cell metastasis. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T.L. Walden, eds.), Kluwer Academic Publishers, Boston, 629-634.

54. Taylor, J.D., Timar, J., Tang, D., Bazaz, R., Chopra, H., Kimler, V. and Honn, K.V. (1992). 12(S)-HETE induces cytoskeleton phosphorylations and rearrangement in melanoma cells. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T.L. Walden, eds.), Kluwer Academic Publishers, Boston, 635-638.

55. Timar, J., Liu, B., Bazaz. R., Taylor, J.D. and Honn, K.V. (1992). Fatty acid modulation of cancer cell spreading and cytoskeleton rearrangement. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T.L. Walden, eds.), Kluwer Academic Publishers, Boston, 639-643.

56. Duniec, Z.M., Marnett, L.J. and Honn, K.V. (1992). Transformation of exogenous arachidonic acid into a new metabolite, 12-KETO-5, 8, 10, 14-Eicosatetraenoic acid by Lewis lung carcinoma cells: Implications in tumor cell metastasis. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, (S. Nigam, K.V. Honn, L.J. Marnett, and T.L. Walden, eds.), Kluwer Academic Publishers, Boston, 667-670.

57. Honn, K.V., Tang, D.C., and Chen, Y.Q. (1992). Adhesion molecules and site-specific metastasis.   In: Thrombosis: An Update, (G.G.Neri Serneri, G.F. Gensini, R. Abbate, D. Prisco, eds.), Scientific Press, Florence, 269-303.

58. Honn, K.V. and Chen, Y.Q. (1992). Prostacyclin, hydroxy fatty acids and cancer metastasis. In: Prostacyclin: New Perspectives in Basic Research and Novel Therapeutic Indications, (G.M. Rubanyi and J.R. Vane, eds.), Elsevier Science Publ B.V., Amsterdam, 181-200.

59. Tang, D.G. and Honn, K.V. (1994). Eicosanoids and tumor cell metastasis. In: Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy, (J.E. Harris, D.P. Braun, K.U. Anderson, eds.), CRC Press, Boca Raton, 73-108.

60. Honn, K.V., Chen, Y.Q. and Tang. D. (1994). Interactions among platelets, tumor cells and the vessel wall. In: Principles of Cell Adhesion, (M. Steiner and P.D. Richardson, eds.), CRC Press, Boca Raton, 317-335..

61. Gao, X. and Honn, K.V. (1995). Biological properties of 12(S)-HETE in cancer metastasis. In: Adv. Prostaglandins, Thromboxane and Leukotriene Res, Volume 23, (B. Samuelsson, P. W. Ramwell, R. Paoletti, G. Golco, E. Grunstrom and S. Nicosia, eds.), Raven Press Ltd., New York, 439-444.

62. Timar, J., and Honn, K.V. (1995). Integrin expression in tumor progression-role of signaling mechanisms. In: Tumor Matrix Biology, (R. Adany, ed.), CRC Press, Boca Raton, 145-171.

63. Tang, D.G., Honn, K.V. (1996). Adhesion molecules and tumor cell-vasculature interactions: Modulation by bioactive lipid molecules. In: Attempts to Understand Metastasis Formation II Regulatory Factors, (U. Gunthert and V. Birchmeir, eds.), Springer, Berlin, 69-88.

64. Gao, X., Hagmann, W., Zacharek, A., Wu, N., Lee, M., Porter, A.T., and Honn, K.V. (1997). Eicosanoids, cancer metastasis, and gene regulation: An overview. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Kluwer Academic Publishers, Boston, 545-555.

65. Hagmann, W., Maher, R., and Honn, K.V. (1997). Intracellular distribution activity and Ca2+-dependent translocation of 12-Lipoxygenase in Lewis lung tumor cells. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Kluwer Academic Publishers, Boston, 57-64.

66. Chen, Y.G., Hagmann, W., and Honn, K.V. (1997). Regulation of 12(S)-HETE production in tumor cells. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Plenum Press, New York, 159-166.

67. Tang, D.G., Honn, K.V. (1997). Role of protein kinase C and phosphates in 12(S)-HETE-induced tumor cell cytoskeletal reorganization. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Plenum Press, New York, 349-361.

68. Siletti, S., Timar, J., Honn, K.V., and Raz, A. (1997). Regulation of tumor cell motility by 12(S)-HETE. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiatio Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Plenum Press, New York, 683-692.

69. Liu, B., Maher, R. De Jonckherre, J.P., Popat, R.U., Stojakovic, S., Hannun, Y.A., Porter, A.T., and Honn, K.V. (1997). 12(S)-HETE increases the motility of prostate tumor cells through selective activation of PKCa. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Plenum Press, New York, 707-720.

70. Timar, J., Bazaz, R., Tang, D.G., Kimler, V., Taylor, J.D., and Honn, K.V. (1997). Post-translational regulation of surface integrin expression in tumor cells by 12(S)-HETE. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.), Plenum Press, New York, 757-764.

71. Honn, K.V. and Tang, D.G. (1997). Eicosanoid 12(S)-HETE upregulates endothelial cell avb3 integrin expression and promotes tumor cell adhesion to vascular endothelium. In: Eicosaniods and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 400, (K.V. Honn, L.J. Marnett, and S. Nigam, eds.) Plenum Press, New York, 765-774.

72. Gao, X., Porter, A.T., Honn, K.V. (1997). Involvement of the multiple tumor supressor genes and 12-Lypoxygenase in human prostate cancer: Therapeutic implications. In: Eiconsanoids and other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 407, (K.V. Honn, L.J. Marnett, S. Nigam, R.L. Jones, and P.Y-K. Wong, eds.), Plenum Press, New York, 41-53.

73. Trikha, M., Honn, K.V. (1997). Role of 12-Lipoxygenase and protein kinase C in modulating the activation state of the integrin allbb3 on human tumor cells. In: Eicosanoids and other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 407, (K.V. Honn, L.J. Marnett, S. Nigam, R.L. Jones, and P.Y-K. Wong, eds.), Plenum Press, New York, 55-60

74. Timar, J., Tovari, J., Szekeres, K., Kagawa, D. and Honn, K.V. (1997). Key determinants of the invasion mechanism of melanoma (Role for a new signaling pathway). In: Eicosanoids and other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 407, (K.V. Honn, L.J. Marnett, S. Nigam, R.L. Jones, and P. Y-K. Wong, eds.), Plenum Press, New York, 303-310.

75. Tang, D., Porter, A.T., and Honn, K.V. (1997). Critical role of arachidonate lipoxygenase in regulating apoptosis. In: Eicosanoids and other Bioactive Lipids in Cancer Inflammation and Radiation Injury, Volume 407, (K.V. Honn, L.J. Marnett, S. Nigam, R.L. Jones, and P.Y-K. Wong, eds.), Plenum Press, New York, 405-411.

76. Tang, D.G., Taylor, J.D., Porter, A.T. and Honn, K.V. (1997). Dual regulatory role of cyclooxygenase and lipoxygenase and their products in cell survival and apoptosis. In: Frontiers in Bioactive Lipids , (J. Vanderhoek, ed.), Plenum Press, New York, 133-139.

77. Timar, J., Rax, A., and Honn, K.V. (1997). Characteristics of the signal transduction pathways of invasion in melanoma cells. In: Growth Disorders of the Pigment Cell, (B. Lyengar, ed.), Churchill Livingstone, London, 303-310.

78. Tang, K. and Honn, K.V. (1997). Lipoxygenase metabolites and cancer metastasis. In: Dietary Fat and Cancer: Genetic and Molecular Interactions, (J. Cohen, ed.), Plenum Press, New York, 71-80.

79. Tang, K. and Honn, K.V. 12 (S)-HETE in cancer metastasis. 1998. In: Lipoxygenases and Their Metabolites: Biological Functions, (S. Nigam and C. Pace-Asciak, eds.), Plenum Press, New York. (in press).

80. Trikha, M. and Honn, K.V. Role of aIIbb3 integrin in metastasis in cell adhesion molecules and matrix proteins.   In: Health and Diseases, (S. Mousa, ed.), Lande Bioscience, Texas, 53-69.

81. Wood, D.P. and Honn, K.V. Introduction. In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds.), Vol. 3, pgs. 1-7, JAI Press, Greenwich. 1999.

82. Tang, K. and Honn, K.V. 1999. Apoptosis and Prostate Cancer. In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds.), Vol. 3, 123-138. JAI Press, Greenwich.

83. Gao, X. and Honn, K.V. 1999. Molecular biology of prostate cancer: Tumor suppressor genes. In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds.), Vol 3. pgs. 85-122, JAI Press, Greenwich.

84. Gao, X. and Honn, K.V. 1999. Tumor markers for prostate cancer. In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds.), Vol. 3, pgs. 47-84, JAI Press, Greenwich.

85. Trikha, M. and Honn, K.V. 1999. Integrins in Prostate Cancer. In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds.), Vol. 3, pgs. 201-212, JAI Press, Greenwich.

86. Nie, D. and Honn, K.V. 1999. Angiogenesis in Prostate Cancer, In: Advances in Oncobiology in Prostate Cancer, (D.P. Wood and K.V. Honn, eds), Vol. 3, pgs. 139-154, JAI Press, Greenwich.

87. Tang, K., Nie, D., and Honn, K.V. 1999. Role of autocrine motility factor in a 12-lipoxygenase dependent anti-apoptotic pathway. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 4. Advances in Experimental Medicine and Biology. Vol. 469, pgs. 583-590. Plenum Press, New York

88. Nie, D., Hillman, G.G., Geddes, T., Tang, K., Pierson, C., Grignon, D.J., and Honn, K.V. 1999. Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 4. Advances in Experimental Medicine and Biology. Vol. 469, pgs. 623-630. Plenum Press, New York

89. Timar, J., Raso, E., Honn, K.V., and Hagmann, W. 1999. 12-lipoxygenase expression in human melanoma cell lines. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 4. Advances in Experimental Medicine and Biology. Vol. 469, pgs. 617-622. Plenum Press, New York

90. Szekeres, C.K., Trikha, M., and Honn, K.V. 2002.   12(S)-HETE, Pleiotropic Functions, Multiple Signaling Pathways. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases, 5. Advances in Experimental Medicine and Biology. (Honn, K.V., Marnett, L.J., Nigam, S, Dennis, E., Serhan, C., eds) Plenum Press, New York 507:509-15.

91. Kandouz, M., and Honn, K.V. 2002.   Eicosanoids Regulation of Transcription Factors in PC-3 Prostate Cancer Cells.. In: Eicosanoids and Other Bioactive Lipid Cancer, Inflammation, and Related Diseases, 5. Advances in Experimental Medicine and Biology. (Honn, K.V., Marnett, L.J., Nigam, S, Dennis, E., Serhan, C., eds)   Plenum Press, New York 507:563-8.

92. Nie, D., Che, M., Gignon, D., Tang, K., and Honn, K.V. 2002. Role Of Eicosanoids In Prostate Cancer Progession.   In: Prostate Cancer: New Horizons in Research and Treatment.   (Cher, M., Honn, K.V. and Raz, A., eds). Kluwer Press, New York. 59-70.

·         I Winter Prostaglandin Conference, Snowbird, UT, 2/9/80.

·         G.M. Surgical Research Conference, Memorial Sloan-Kettering, New York, New York. 6/9/80.

·         Multi-disciplinary Congress of the Belgian Medical Society, Catholic University, Leuven, Belgium. 3/6/82.

·         UCLA Symposia on Molecular and Cellular Biology, Los Angeles, California. 1/24/86.

·         VIth International Conference on Prostaglandins and Related Compounds, Florence, Italy. 6/4/86.

·         1986 International Conference on Prostaglandins and Cancer, Rome, Italy. 6/9/86.

·         2nd International Conference on Anticarcinogenesis and Radiation Protection. 3/10/87.

·         XIth International Congress on Thrombosis and Haemostasis, Brussels, Belgium. 7/09/87.

·         Taipei Conference on Prostaglandins & Leukotriene Research, Taipei, Taiwan. 4/23/88.

·         1988 Sapporo Cancer Seminar, Sapporo, Hokkaido, Japan. 7/9/88.

·         International Symposium on New Concepts in Cancer, Castres, France. 4/13/89. 

·         1990 Gordon Research Conference on Oxygen Radicals in Biology, Ventura, California. 1/31/90.

·         Banbury Center Conference, Cold Spring Harbor, New York. 4/18/90.

·         VIIth International Conference on Prostaglandins and Related Compounds, Florence, Italy. 5/30/90.

·         International Conference on Prostaglandins, Leukotrienes & Lipoxins, Washington D.C. 5/16/91.

·         XIIIth Congress of the International Society on Thrombosis and Haemostasis, Amsterdam,

·         Netherlands. 7/1/91.

·         EACR Satellite Meeting, New Trends in the Therapy of Tumor Dissemination, Budapest, Hungary, 4/1/93.

·         9th International Conference on Prostaglandins and Related Compounds, Florence, Italy,

·         June 4 -12, 1994.

·         10th International Conference on Prostaglandins and Related Compounds, Vienna, Austria, September 22-27, 1997.

·         “Lipoxygenases and angiogenesis.” International Conference on Phospholipase A2, Berlin, Germany, 05/28/99.

·         “Role of endothelial cell and prostate cancer cell 12-lipoxygenase in tumor induced angiogenesis.” 04/19/99. Monsanto, St. Louis, Missouri.

·         “Lipoxygenases and tumor angiogenesis.” 05/06/99. National Institute of Environmental Health Sciences, Raleigh Durham, North Carolina.

·         “Tumor angiogenesis: Role of 12(S)-HETE.” 05/26/99. Schering, Berlin, Germany.

·         “Angiogenesis, Eicosanoids and Prostate Cancer.” 04/15/99. 1999 Keystone Symposia, Keystone, Colorado.

·         “12(S)-HETE and Angiogenesis.” 5/26/99. Schering AG Berlin, Germany. 

·         “The Platelet in Tumor Progression” 5/30/99. University of Vienna, Vienna, Austria.

·         “Polyunsaturated Fatty Acids in Cancer” Cooperative Research and Information Institute Omega-III Fatty Acid Workshop, 6/20/99, Baltimore, MD.

·         “Lipoxygenases and Tumor Angiogenesis” New York Academy of Sciences Conference on Lysophospholipids and Eicosanoids in Cancer, Cardiovascular and Neurodegenerative Diseases. 6/28/99 New York, NY.

·         “Role of Eicosanoids in Cancer and Tumor Metastasis” Ernst Schering Research Foundation Workshop on “Advances in Eicosanoid Research”, 6/30/99, San Francisco, CA.

·         “Update on Eicosanoids in Prostate Cancer” Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases, September 12-15, 1999, Boston, MA.

·         “Eicosanoid Regulation of Angiogenesis” 2000 Keystone Symposia: Experimental and Clinical Regulation of Angiogenesis, 3/2-7/00, Salt Lake City, UT.

·         “Integrins in Melanoma” AACR Special Conference on Melanoma: Basic Biology and Immunological Approaches to Therapy. 5/3-7/00.

·         Chemoprevention Workshop of the Board of Scientific Counselors, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 6/25/1981.

·         Chesapeake Conference on Hemostasis and Malignancy, Baltimore, Maryland. 6/26/1981.

·         National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. 7/17/1981.

·         Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut. 8/11/1981.

·         Dartmouth University School of Medicine, White River Junction, Vermont. 9/10/1981.

·         The Upjohn Company, Kalamazoo, Michigan. 9/12/1981.

·         Warner Lambert/Parke Davis, Ann Arbor, Michigan. 9/17/1981.

·         Symposium on Nafazatrom (Bay g 6575). Port Chester, New York. 10/2/1981.

·         Ciba/Geigy, Summit, New Jersey. 10/23/1981.

·         Department of Chemistry, Wayne State University, Detroit, Michigan. 10/30/1981.

·         Comprehensive Cancer Center of Metropolitan Detroit, Detroit, Michigan. 11/5/1981.

·         Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan. 12/4/1981.

·         M.D. Anderson Hospital and Tumor Institute, Houston, Texas. 1/14/1982.

·         M.D. Anderson Hospital and Tumor Institute, Houston, Texas. 1/15/1982.

·         New York University, School of Medicine, Departments of Medicine and Pathology, New York, New York. 2/29/1982.

·         Vth International Conference on Prostaglandins. Florence, Italy. 5/21/1982.

·         Southeastern Cancer Study Group Meeting, Longboat Key, Florida. 6/22/1982.

·         Symposium on Noncytotoxic Approaches to Cancer Chemotherapy, Warner Lambert Co., Ann Arbor, Michigan. 7/22/1982.

·         NFCR-Cancer Research Association Symposium "Protective Agents in Human and Experimental Cancers", Brunel University, Uxbridge, England. 9/1/1982.

·         Fifth National Thrombosis Conference, American Heart Association, Dallas, Texas. 11/15/1982.

·         International Symposium–Basic Mechanisms and Clinical Treatments of Tumor Metastasis, Fukuoka Cancer Society, Fukuoka, Japan. 12/7/1982.

·         International Study Center for Environmental Health Sciences Inc., Washington, D.C. 12/14/1982.

·         Biological Approaches to Breast Cancer Prognosis and Treatment, Michigan Cancer Foundation, Detroit, Michigan. 12/15/1982.

·         Inflammation Research Association Meeting, New York, New York. 1/18/1983.

·         Cancer Invasion and Metastasis, Thirty-Sixth Annual Symposium on Fundamental Cancer Research, M.D. Anderson Hospital and Tumor Institute, Houston, Texas. 3/2/1983.

·         American Cancer Society 25th Annual Science Writers Symposium, San Diego, California. 3/23/1983.

·         Nafazatrom Workshop, Miles Inc., New Haven, Connecticut. 6/24/1983.

·         Ciba-Geigy, Summit, New Jersey. 9/13/1983.

·         Roswell Park Memorial Institute, Buffalo, New York. 10/7/1983.

·         Current Concepts in Medical Oncology, Memorial Sloan-Kettering, New York, New York. 10/27/1983.

·         U.S./Italy Agreement Workshop, NCI/NIH, Bethesda, Maryland. 10/28/1983.

·         Laboratory Testing in Cancer: Current Concepts and Applications, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas. 2/9/1984.

·         E.I. DuPont de Nemours and Company, Wilmington, Delaware. 3/26/1984.

·         Basic Science for the Clinician - Oncology and Chemotherapy, Baptist Medical Center, Birmingham, Alabama. 3/28/1984.

·         Joint Great Lakes and Central Regional Meeting–American Chemical Society, Kalamazoo, Michigan. 5/24/1984.

·         Anticoagulants and the Treatment of Cancer (RS-233), Veterans Administration Cooperative Study Group, Chicago, Illinois. 5/31/1984.

·         Mechanisms of Metastasis: Potential Therapeutic Implications, Harper Hospital, Detroit, Michigan. 6/2/1984.

·         VIII International Congress on Thrombosis, Istanbul, Turkey. 6/6/1984.

·         Thomae Pharmaceuticals, Bieberach, West Germany. 6/14/1984.

·         University of Zurich, Zurich, Switzerland. 6/16/1984.

·         Treatment of Metastasis: Problems and Prospects, London, England. 10/16/1984.

·         Kyoto Conference on Prostaglandins, Kyoto, Japan. 11/26/1984.

·         Chinese University of Hong Kong, New Territories, Hong Kong. 12/3/1984.

·         Squibb Institute for Medical Research, Princeton, New Jersey. 4/4/1985.

·         FASEB, Anaheim, California. 4/24/1985.

·         Upjohn, Brook Lodge Symposium, Augusta, Michigan. 9/16/1985.

·         Mario Negri Institute, Milan, Italy. 9/20/1985.

·         UCLA Symposia on Molecular and Cellular Biology, Los Angeles, California. 1/24/1986.

·         6th International Conference on Prostaglandins and Related Compounds, Florence, Italy. 6/4/1986.

·         1986 International Conference on Prostaglandins and Cancer, Rome, Italy. 6/9/1986.

·         Schering AG, West Berlin, Germany. 8/28/1986.

·         Joseph Stefan Institute, Ljubljana, Yugoslavia. 9/1/1986.

·         University of Bologna, Bologna, Italy. 9/3/1986.

·         Mario Negrio Institute, Milan, Italy. 9/4/1986.

·         Thomae Pharmaceutical, Biberach, W. Germany. 9/8/1986.

·         Institut de Recherches Scientifiques Sur le Cancer, Villejuif, France. 9/12/1986.

·         Royal Marsden Hospital, Sutton, Surrey, England.   9/16/1986.

·         Gray Laboratories, Middlesex, England. 9/17/1986.

·         Satellite Workshop, Micro-circulation Society, Washington, D.C. 3/27/1987.

·         Switzerland Institute for Experimental Cancer Research, Lausanne, Switzerland. 7/13/1987.

·         Semmelweiss University, Budapest, Hungary. 7/22/1987.

·         Pharmaceutical and Biochemical Research Institute, Prague, Czechoslovakia. 7/29/1987.

·         Maria Sklodowska- Curie Memorial Institute of Oncology, Warsaw, Poland. 7/31/1987.

·         Department of Biochemistry, Frie Universitat, West Berlin. 8/3/1987.

·         Association for International Cancer Research, West Berlin. 9/1/1987.

·         Schering AG, West Berlin. 9/3/1987.

·         Tokushima University, Tokushima, Japan. 7/11/1988.

·         Ono Research Institute, Tokyo, Japan. 7/13/1988.

·         Ono Research Institute, Osaka, Japan. 8/25/1989.

·         MSUCTC & OLACC (The Ohio Valley Lake-Erie Association of Cancer Centers), East Lansing, Michigan. 9/9/1989.

·         Schering AG, West Berlin. 12/22/1989.

·         Federation of American Societies for Experimental Biology 1990 meeting, Washington, D.C. 4/3/1990.

·         15th International Cancer Congress, Hamburg, Germany. 8/17/1990.

·         Monsanto Company, St. Louis, Missouri. 10/3/1990.

·         Department of Otolaryngology, Wayne State University, Detroit, Michigan. 10/16/1990.

·         Ono Research Institute, Osaka, Japan. 11/7/1990.

·         Michigan State University, Department of Pharmacology and Toxicology, East Lansing, Michigan. 1/22/1991.

·         Prostaglandins, Leukotrienes Lipoxins & PAF, XIth Washington International Spring Symposium, Washington, D.C. 5/16/1991.

·         82nd Annual Meeting of the American Association for Cancer Research. 5/18/1991.

·         XIIIth Congress of the International Society on Thrombosis and Haemostasis, Amsterdam. 7/1/1991.

·         Schering AG, West Berlin. 7/9/1991.

·         Cytokines, Lipid Mediators as Regulators of Cell Function (FASEB). Copper Mt., CO. 8/15/1991.

·         2nd International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Berlin. 9/20/1991.

·         5th International Symposium on Prostacyclins in the Cardiovascular System, Vienna. 9/25/1991.

·         Semmelweis Medical University, Institute of Pathology and Experimental Cancer Research, Hungary. 9/30/1991.

·         SmithKline Beecham Pharmaceuticals, King of Prussia, PA. 10/22/1991.

·         The Endothelium, National Heart and Lung Institute, Royal Brompton Hospital, London. 11/20/1991.

·         The Wellcome Foundation, The Department of Biological Sciences, London. 11/21/1991.

·         The William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London. 11/22/1991.

·         Humboldt University, Department of Biochemistry, Berlin. 11/25/1991.

·         M.D. Anderson Cancer Center, University of Texas, Department of Carcinogenesis, Smithville, TX, 12/13/1991.

·         1992 Winter Prostaglandin Conference, Keystone, CO, 1/10/1992.

·         Laboratory of Molecular Biophysics National Institute of Environmental Health Sciences,

·         Research Triangle Park, NC. 3/17/1992.

·         Sphinx Pharmaceuticals, Chapel Hill, NC. 3/18/1992.

·         Department of Medicine, Division of Hematology/Oncology, Duke University, Durham, NC

·         3/19/1992.

·         Kresgee Eye Institute, Wayne State University, Detroit, MI. 3/26/1992.

·         Thromboembolic Diseases XII Congress on Thrombosis, Florence, Italy. 5/19/1992.

·         Universite De Rennes, Department of Chimie Organique, Rennes, France. 6/12/1992.

·         International Society for Free Radical Research, 6th Biennial Meeting Torino, Italy. 6/17/1992.

·         17th European Conference on Microcirculation, London, UK. 7/8/1992.

·         Department of Chemistry, Wayne State University, Detroit, MI. 9/25/1992

·         Department of Urology, Wayne State University, Detroit, MI. 11/20/1992.

·         Opinion Leader Seminar on Cicaprost Schering AG Frankfurt, Germany. 2/6/1993.

·         Opinion Leader Workshop on Calcium Channel Blockers and Radioprotection Bayer AG Cologne, Germany. 3/25/1993.

·         New Trends in the Therapy of Tumour Dissemination, Budapest, Hungary. 4/1/1993.

·         Institut de Recherches Servier, Paris, France. 4/6/1993.

·         3rd International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Washington DC. 10/12/1993.

·         Grace Cancer Drug Center Chemotherapy Seminar Series, Roswell Park, Buffalo, New York. 12/13/1993.

·         Department of Urology, Wayne State University, Detroit, MI, 10/20/1993.

·         Cornell University, Ithaca, New York, 4/21/1994.

·         NIEHS, Raleigh, North Carolina, 5/9/1994.

·         Duke University, Durham, North Carolina, 5/10/1994.

·         New Jersey's University of Health Sciences, School of Osteopathic Medicine, Distinguished Lecture Series, Stratford, New Jersey, 5/16/1994.

·         9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, 6/6/1994.

·         Growth Control and Therapy of Cancer, Budapest, Hungary, 8/21-24/1994.

·         University of Heidelberg, Heidelberg, Germany, 8/25-28/1994

·         Syntex Research Institute, Palo Alto, California 12/14/1994

·         FASEB Summer Conference, Cytokines & Lipid Mediators, Saxton River, VT 7/8-7/13/1995

·         FASEB Summer Conference, Thrombin, Copper Mt., Colorado, 8/13-8/17/1995

·         4th Intl. Conf. on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Radiation Injury, Hong Kong, 10/7-10/13/1995

·         University of Cincinnati, Dept. of Pathology, 11/2/1995

·         AICR, Annual Research Conference, Dietary Fat and Cancer: Genetic and Molecular Interactions, Washington, DC, 8/19-20/1996.

·         Cambridge Symposium, Immunology and Immunotherapy of Metastasis. Lake Tahoe, California, 5/11-15/1996.

·         Bioactive Lipids in Cancer and Inflammation. Universitatklinikum Benjamin Franklin, Berlin, Germany 9/20/1996

·         International Conference on Prostaglandins and Related Lipids, Vienna, Austria, 9/22-27/1996

·         Lipoxygenases and their products: Biological Function, Malta 6/21-24/1997

·         FASEB Summer Conference, Cytokines and Lipid Mediators, Saxton River, VT 6/7-6/12/1997

·         NCI Prostate Cancer Progress Review Group, Chantilly, VA 6/29-7/1/1997

·         5th Intl. Conf. on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Related Diseases, La Jolla, CA, 09/17 - 09/20/1997.

·         6th Intl. Conf. on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Related Diseases, Boston, MA.

·         Eicosanoids in Angiogenesis. Ernst Schering Research Foundation Workshop on “Advances in Eicosanoid Research” 6/30/01 San Francisco, CA

·         “12-Lipoxygenase and Tumor Cell Apoptosis”. 7th International Conference on Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases. October 14-17, 2001, Nashville, TN.

·         “Lipoxygenases in cell proliferation and apoptosis of prostate cancer cells”. 8th International Conference on Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases, September 7-10, 2003, Chicago, IL.

·         “Lipoxygenases and angiogenesis”. 5th Annual Winter Eicosanoid Conference. Baltimore, MD, March 9–12, 2003

·         “Role Of Thromboxane In Prostate Cancer Progression”. 7th Annual Winter Eicosanoid Conference, March 20-23, 2005, Baltimore MD.

·         “Thromboxane: Potential Role in Prostate Cancer Invasion”. May 27, 2005, Medical University of South Carolina, Department of Biochemistry, Charleston, SC.

·         “Thromboxane and Tumor Invasion and Metastasis”. October 13, 2005, Medical College of Wisconsin, Department of Pharmacology, Milwaukee WI.

·         “Thromboxane Synthase and TP Receptors In Tumor Progression”. 9th International Conference on Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases, September 11-14, 2005, San Francisco.

·         “Thromboxane: Potential Role in Prostate Cancer Progression”, January 11-13, 2006, Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.

·         “12-LOX, Angiogenesis and Cancer”, Keystone Symposia – Molecular Targets for Cancer Prevention, March 6-10, 2006, Tahoe City, CA.

·         “12-Lipoxygenase in Prostate Cancer Angiogenesis”. March 27, 2006, Medical University of South Carolina, Department of Radiation Oncology, Charleston, SC.

·         “12-Lipoxygenase Role in Cancer Progression“, June 6, 2006, Medical University of South Carolina, Department of Radiation Oncology, Charleston, SC.

·         “Eicosanoids and Prostate Cancer Progression”. September 22, 2006, Southern Illinois University – School of Medicine, Department of Medical Microbiology, Immunology and Cell Biology, Springfield, IL

·         “12-Lipoxygenase and prostate cancer angiogenesis in the normoxic and hypoxic microenvironment”, Keystone Symposia – Host Cell Interaction & Response to Cancer Cell, January 21 – 26, 2007, Keystone, CO

·         “Thromboxane in Prostate Cancer Progression”, Recent Advances in Prostate Cancer Research and Treatment, July 5-6, 2007, Washington, DC

·         “Thromboxane Synthase and TP Receptor in Tumor Progression”, FASEB Research Conference, Lipid Signaling Pathways in Cancer, August 11-15, 2007, Indian Wells, CA

·         “Characterization of a Novel 12(S)-HETE Receptor an Role in Prostate Cancer Progression”, Dept of Defense, Prostate Cancer Research Program meeting, Sept 6-8, 2007, Atlanta, GA

·         “12-Lipoxygenase and the regulation of prostate cancer angiogenesis under normoxic and hypoxic conditions”, Bioactive Lipids in Cancer, Inflammation, and Related Diseases, Sept 15-19, 2007, Montreal, Canada

·         “12-Lipoxygenase in Cancer Progression”, Frontiers in Cancer Prevention Research (AACR), December 4-7, 2007, Philadelphia, PA

·         “12-Lipoxygenase and Tumor Angiogenesis”, 10^th Annual Winter Eicosanoid Conference, March 9-12, 2008, Baltimore, MD

·         “Thromboxane in Prostate Cancer Progression”, Frontiers in Prostate Cancer Research, April 3-7, 2008, San Francisco, CA

GRANT SUPPORT (CAREER TOTAL $21,044,579, 1979 – present)

1.      Prostaglandins and Lysosomal Mediated Tumor Metastasis. WSU Research Development Fund. (P.I., K.V. Honn), 6/1/79 to 5/31/80, $6,760.

2.      New Approach for the Control of Tumor Metastasis. The Milheim Foundation for Cancer Research. (P.I., K.V. Honn), 7/1/80 to 6/30/81, $12,000.

3.      Evaluation of the Antimetastatic Effects of Bay g 6575. Miles Institute for Preclinical Pharmacology. (P.I. , K.V. Honn), 6/1/80 to 5/31/81, $3,000.

4.      Studies on Prostacyclin and Tumor Metastasis. NIH/NCI – R01-CA29405-1 (P.I., K.V. Honn), 10/1/80 to 9/30/83, $104,787.

5.      Studies on Thromboxane Synthetase Inhibitors and Cancer. Comprehensive Cancer Center of Metropolitan Detroit. (P.I., K.V. Honn), 10/1/80 to 9/31/81, $10,000.

6.      Studies on Thromboxane Synthetase Inhibitors as Antimetastatic Agents. American Cancer Society. (P.I., K.V. Honn), 1/1/81 to 12/31/82, $94,151.

7.      Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI – R01-CA29997-1 (P.I., K.V. Honn), 4/1/81 to 3/31/84, $158,339.

8.      Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/81 to 1/31/ 82, $59,000.

9.      Studies on the Antimetastatic Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/81 to 1/31/82, $5, 060.

10.     Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/82 to 1/31/83, $ 57,000.

11.     Cancer Chemoprevention and Arachidonate Metabolism. NIH/NCI, R01 L.J. Marnett, K.V. Honn and B.F. Sloane, (P.I. L.J. Marnett), 8/1/82 to 7/31/85, $350,000.

12.     Evaluation of the Antitumor and/or Antimetastatic Activities of CGS-13080 and CGS-14854. Ciba-Geigy Corporation. (P.I., K.V. Honn), 10/1/82 to 9/30/83, $14,460.

13.     Evaluation of Antitumor and Antimetastatic Activities of Thromboxane Synthetase Inhibitors. Pfizer Corporation. (P.I., K.V. Honn), 10/1/82 to 9/30/83. $15,000.

14.     Development of Monoclonal Antibodies to Cathepsin B. HarperGrace Hospitals. K.V. Honn and B.F. Sloane, (P.I., K.V. Honn), 7/1/83 to 8/31/84, $127,000.

15.     Studies on Prostacyclin and Tumor Metastasis. NIH/NCI R01-CA29405-4 (P.I., K.V. Honn), 7/7/83 to 12/31/86, $189,183.

16.     Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI R01-CA36481-1. B.F. Sloane and K.V. Honn, (P.I.,B.F. Sloane), 12/1/83 to 11/30/86, $341,000.

17.     Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI R01 CA29997-4. (P.I.,K.V. Honn), 4/1/84 to 12/31/87, $341,113.

18.     Studies on Metastasis. Harper/Grace Hospitals. K.V. Honn, L.J. Marnett and B.F. Sloane, (P.I., K.V. Honn), 1/1/85 to 63086, $160,000.

19.     Studies on Metastasis. Thomae Pharaceutical. K.V. Honn and L.J. Marnett (P.I., K.V. Honn), 1/1/85 to 12/31/85, $60,000.

20.     Studies on Metastasis. Harper-Grace Hospitals. K.V. Honn, L.J. Marnett, B.F. Sloane, C.J. Johnson and J.M. Onoda (P.I., K.V. Honn), 12/1/85 to 8/31/87, $175,000.

21.     Development of Lipoxygenase Inhibitors. Harper/Grace Hospitals. K.V. Honn, L. J. Marnett, C. Johnson (P.I. K. V. Honn), 9/1/87 to 6/30/89, $250,000 (direct costs).

22.     Role of Platelets in Hematogenous Metastasis. American Cancer Society. (P.I., K.V. Honn), 1/1/86 to 12/31/87, $190,000.

23.     Role of Platelets in Hematogenous Metastasis. American Cancer Society. K.V. Honn (P.I. K.V. Honn) Interim Funding 1/1/88 to 6/30/89, $48,000.

24.     Studies on Radiporotection, Coagulation and Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 10/1/88 to 9/30/89, $100,297 (direct costs).

25.     Studies on Metastasis. Thomae Pharmaceutical. K.V. Honn and L.J. Marnett, (P.I., K.V. Honn), 1/1/87 to 12/31/90, $60,000 (direct costs).

26.     Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI – R01-CA47115-1 (P.I. K.V. Honn), 5/1/88 to 4/31/92, $418,323 (direct costs).

27.     Studies on 12-Lipoxygenase–Ono Pharmaceuticals. K.V. Honn, C.R. Johnson, and L.J. Marnett (P.I. K.V. Honn). 1/1/89 to 12/31/92, $2,525,000 (direct costs).

28.     Studies on Radiporotection, Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 1/1/90 to 12/31/93, $104,921 (direct costs).

29.     Supplemental Equipment Grant for Metastasis Program–Harper Grace Hospitals. J.M. Onoda and K.V. Honn (P.I. K.V. Honn), 5/1/91 to 9/30/94, $157,000 (direct costs).

30.     Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI Bonus Grant R01-CA36481-4. B.F. Sloane and K.V. Honn, (P.I., B.F. Sloane), 7/1/87 to 6/30/93, $493,046 (direct costs).

31.     New Signal Transduction Pathways in Metastatic Melanoma Cells.  NATO Linkage Grant (P.I. K.V. Honn) 1/1/93 to 12/31/95, $26,000 (direct costs).

32.     Signal Transduction in Tumor Metastasis. Fogarty International Research Collaboration Award. (P.I. K.V. Honn) 9/1/93 to 8/31/96, $60,000 (direct costs).

33.     Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis.    Cancer Research Foundation of America (P.I.., K.V. Honn) 1/1/97 to 12/31/97, $25,000 (direct costs).

34.     Role of Signaling in the Progression of Melanoma. NATO Linkage Grant (P.I., K.V. Honn) 1/1/95 to 12/31/97, $26,000 (direct costs).

35.     Studies on Metastasis, Harper Hospital Development Fund (P.I. K.V. Honn), 9/1/94 - 8/30/98, $248,000 (direct costs).

36.     Prognostic Markers for Prostate Cancer, Harper Hospital Development Fund, (P.I. K.V. Honn) 9/1/94 to 6/30/98, $99,000 (direct costs).

37.     Metastatic Studies: Potential Involvement of Integrin b in Tumor Progression and Metastasis). Harper Hospital Development, (P.I. K.V. Honn) 11/1/94 to 10/31/98, $100,000 (direct costs).

38.     Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI. R01CA47115-6, (P.I. K.V. Honn), 03/01/95 to 02/28/99, $1,178,331 (direct and indirect costs).

39.      Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis.    Cancer Research Foundation of America (P.I.., K.V. Honn) 04/15/97 to 04/15/99, $55,000 (direct costs).

40.     Studies on Metastasis. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $248,000 (direct costs).

41.     Prognostic Markers for Prostate Cancer. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $99,000 (direct costs).

42.     Bioactive Lipids: Role in Prostate Cancer Angiogenesis. DOD/Army (P.I., K.V. Honn) 9/30/98 to 3/30/01, $468,750 (direct and indirect costs).

43.     Arachidonate Acid 12-Lipoxygenase Inhibitors for Anti-Angiogenesis Therapy of Prostate Cancer. CAPCure (P.I. KV Honn), 01/01/99 to 12/31/01, $75,000.

44.     Role of Eicosanoids in Tumor Cell Metastasis. NIH/NCI. CA R0129997, (P.I. K.V. Honn), 02/01/96 to 01/31/00, $988,291.

45.     Development Grant - PCa Progression and Metastasis, NIH/NCI. CA1R21 69845-01 (P.I. K.V. Honn) 09/01/95 - 08/31/01, $1,028,820 (direct costs).

46.     Bioactive Lipids: Role in Prostate Cancer Angiogenesis, Part II. DoD Army-Phase II (competitive renewal) (P.I. K.V. Honn) 6/30/01 - 6/29/03, $552,276 (direct + indirect costs).

47.     Ectopic Expression of Platelet Integrin aIIbb3 and the Progression of Human Melanoma. NATO Linkage Grant (P.I. K.V. Honn), 04/15/99 to 03/31/2001, $11,500 (direct costs).

48.     Thromboxane Synthase as a Target for Anti-Angiogenesis Therapy of Prostate Cancer. Cancer Research Foundation of America. (P.I. K.V. Honn) 4/15/01-4/14/03, $60,000 (direct costs only).                          

49.     Randomized Clinical Trial of Zileuton in Persons with Bronchial Dysplasia, NIH/NCI – Contract NO1-CN-05022 (O. Kucuk, H. Pass, T. Budd, K.V.Honn (P.I. O. Kucuk) ), 9/01/01-9/01/05, $1,402,882 (total direct). 

50.         Thromboxane Synthase and Prostate Cancer Progression, DoD/Army, (P.I. K.V. Honn), 12/1/01 - 07/15/05, $558,750.

51.         Formulation and Evaluation of a Prostate Cancer Drug, Phase 1, NIH STTR Phase 1 – 1 R41 CA97863-01 (P.I. K.V. Honn), 10/01/02-2/28/06, $148,000.

52.         Formulation and Evaluation of a Prostate Cancer Drug, Phase 1, NIH STTR Phase 1 – 1 R41 CA97863-01 (P.I. K.V. Honn), 10/01/02-2/28/06, $148,000.

53.         Eicosanoid Regulation of Prostate Cancer Progression: Disruption of Hemidesmosomes and Collaboration in Tumor Invasive Growth, Department of Defense – DAMD17-03-1-0102 (P.I. K.V. Honn), 4/01/03-3/31/07, $ 558,472.

54.         Naturally Occurring Truncated 3 Integrins (b3 and v3) In Prostate Cancer Metastasis. -Department of Defense - W81XWH-04-1-0144 (P.I. Rongxian Jin), Postdoctoral Traineeship Award, 01/01/04 - 1/31/07, $98,000.

55.         Faculty Graduate Research Assistantship. Wayne State University (Internal) (P.I. K.V. Honn), Stipend for graduate student, 8/15/05 - 08/14/06, $20,500.

1.       Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI – 2 R01 CA47115-09A2 (P.I. K.V. Honn) (competitive renewal), 8/01/01-7/31/06, $1,487,060.        

2.       Role of Eicosanoids in Tumor Cell Metastasis. NIH – 5 R01 CA029997-18 (P.I. K.V. Honn). 4/01/04-3/31/09, $1,359,00 (direct and indirect costs).

3.       12-Lipoxygenase as a Target for Radiosensitization, NIH/STTR – 1 R41 CA103564-01A2       (P.I. K.V. Honn), 04/01/05 – 03/31/07, $99,744 (direct and indirect costs).

4.       Characterization of a Novel 12(S)-HETE Receptor and Role in Prostate Cancer Progression. DOD – W81XWH-06-1-0226 (P.I. K.V. Honn), 12/30/05 - 1/29/09, $565,398 (direct and indirect costs).

5.       Role of Thromboxane in Prostate Cancer Progression. NIH/NCI – 1 R01 CA114051-01A1

   (P.I. K.V. Honn), 08/15/06 – 07/31/11, $1,618.313 (direct and indirect costs).

6.   12-Lipoxygenase-Induced Prostate Cancer Angiogenesis and Resistance to Antiangiogenic Therapy. DOD (P.I. K.V. Honn), 02/22/08 – 02/21/11, $563,494 (direct and indirect costs).

7.   12-Lipoxygenase and Prostate Cancer Angiogenesis. Fund for Cancer Research (P.I. K.V. Honn), 08/15/07 – 08/14/08, $75,000 (no indirects).

President and Scientific Director

Children’s Memorial Research Center

Northwestern University

2300 Children’s Plaza, Box 222

Chicago, Illinois 60614-3394

Professor and Endowed Distinguished Scientist

Brigham and Women’s Hospital

3601 Spruce Street

Nashville, TN 37232-0146

M.D. Anderson Cancer Center

Battelle Pulmonary Therapeutics

Mohit Trikha, Ph.D.
Director, Non-Clinical Oncology
Development Sciences and Molecular Oncology
Genentech, Inc.
1 DNA Way
Mail Stop 241B
South San Francisco, CA 94080